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Abstract  
Exposure to arsenic (As) is a global health concern, according to the World 
Health Organization and Agency for Toxic Substances and Disease Registry. Prolonged 
exposure to this naturally occurring chemical has been linked to hyperkeratosis, type II 
diabetes, developmental abnormalities, and cancer. Some of the adverse health effects of 
As may be linked to its ability to alter cellular signal transduction. Recently, published 
work from the Gosse laboratory has shown that inorganic arsenite inhibits the signaling 
cascade leading to mast cell degranulation, a vital immune function, through an as-yet 
unknown mechanism.  
Further work in the Gosse lab has suggested that arsenic’s effect occurs early in 
the degranulation signaling pathway, between receptor aggregation and calcium influx. 
Alternate FcεRI cross-linking methods produced similar As inhibition patterns, 
suggesting an As effect downstream of receptor aggregation.  Calcium ionophore and 
compound 48/80-mediated degranulation responses were not inhibited by As-- evidence 
that arsenic’s effect occurs upstream of calcium influx as well. This thesis will 
concentrate on testing the hypothesis that As disrupts antigen-stimulated tyrosine 
phosphorylation of Syk kinase, a signaling molecule functioning between receptor 
aggregation and calcium influx in mast cells. Using a piceatannol-arsenic combination 
assay it was found that Syk and piceatannol, a competitive inhibitor of Syk, cause an 
additive inhibitory effect on degranulation. Preliminary Phospho-Syk ELISA data 
provides evidence that arsenic may be interfering with the phosphorylation of Syk, a vital 
process during the development of hypersensitivity. Taken together, these data provide 
insight into possible mechanisms of toxicity of arsenic as well as a possible drug target in 
the treatment and prevention of asthma and allergy. 
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1. Introduction 
1.1. Arsenic 
 Arsenic (As) is a metalloid commonly found in the Earth’s crust at an average 
concentration of 2mg/ kg and as high as 100mg/kg as part of copper or lead ores, and 
within minerals in the soil [1]. Elemental arsenic, insoluble in water, is most commonly 
found in the environment combined with oxygen, sulfur, and chlorine, and is known as 
inorganic arsenic in this form. The most common arsenic-containing mineral in the soil is 
arsenopyritein (FeAsS), but arsenic is known to be associated with more than 200 
different other minerals, especially those containing sulfide [1, 2, 3]. In the environment, 
inorganic arsenic can assume two valence states described as arsenite (As(III)) and 
arsenate (As (V)) [4]. Under reducing conditions the trivalent form is most prevalent, 
while in highly oxygenated environments (oxidizing conditions), the pentavalent form 
predominates [1].  Its trivalent form, arsenite, has been shown to be the more toxic of the 
two even in its monomethylated state [5]. The methods for possible toxicity will be 
discussed in later sections.  
 Sources of arsenic are varied and plentiful. Humans can come in contact with 
arsenic through the consumption of contaminated water and food, inhalation of industrial 
emissions from copper or lead smelting, as well as routine occupational exposure. For the 
general population, the most relevant exposure to arsenic is through the consumption of 
contaminated drinking water from wells located near mineral deposits [1, 6]. The levels 
of arsenic in drinking water vary by region but are estimated to range between 1 and 1000 
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ppb (µg/L). However, in areas such as West Bengal, India, Bangladesh, North Mexico, 
Chile and Argentina millions of people are affected by levels of arsenic in their drinking 
water ranging from 50 to 3000 ppb (µg/L)[1, 6]. Areas near sulfide mineralization and 
geochemical sites near Taiwan reported groundwater level of arsenic as high as 1 ppm 
(mg/L) [7]. 
 Contaminated drinking water is the major source of arsenic exposure in humans, 
but consumption of arsenic-bearing foods like shellfish, cereals, and vegetables can also 
be a substantial source. A study of inorganic arsenic in the typical Hong Kong diet found 
levels of arsenic as high as 74 µg/kg (this is elemental arsenic per wet body weight; 
comparable to ppb) in water spinach, and 58 µg/kg (58 ppb) in oysters [9]. The highest 
arsenic-exposure contributing products were cereals with 53.5% contribution to the diet 
of the average Hong Kong citizen, with brown (unpolished) rice having the highest 
concentration of arsenic at 43 µg/kg (43 ppb). The study concluded that the high levels of 
arsenic in these foods are likely due to their aquatic growing conditions [9]. These Hong 
Kong study is one only of many similar studies attempting to elucidate the human dietary 
exposure to arsenic. Closer to home, the Consumer Reports magazine did a study of their 
own. Similar to the Hong Kong study, it was found that cereals were the largest 
contributor of arsenic with uncooked rice topping the charts at levels as high 900 ppb 
(900 µg/mL) [10]. Levels of arsenic in food this high are cause for concern given the 
major health problems that are linked to chronic exposure of arsenic. 
1.2. Arsenic & Human Health 
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 Due to its high prevalence in the environment, there has been a lot of attention on 
how exposure to arsenic affects the human body. Acute arsenic exposure (acute 
poisoning) can occur when the digestion of large amounts (>5mg) of arsenic containing 
products, such as insecticides, occurs. One-time doses of about 5mg of arsenic are 
described as causing minor complications such as vomiting and diarrhea; however, doses 
ranging from 100mg to 300mg can cause skin rashes, cardiomyopathy, seizures, renal 
failure, pulmonary edema and eventually death [11]. Acute poisoning of arsenic is rare 
and often accidental; however, chronic consumption of small doses (for example, 50 
µg/L (or 50 ppb) in drinking water) of arsenic is just as dangerous and a more prevalent 
issue worldwide.  Long term exposure to low levels of arsenic has been linked to health 
issues ranging from hyperpigmentation and keratosis to an increased risk of 
cardiovascular disease, respiratory disease, diabetes mellitus, and cognitive impairment 
[1, 11]. Chronic exposure to arsenic, however, has been most clearly linked with cancer 
development in nearly all organ systems of the body [1, 11, 12]. The U.S Environmental 
Protection Agency released a statement claiming that a lifetime exposure to arsenic as 
low as 1 ppb has been linked to having a significantly higher risk of developing skin 
cancer [6]. It is clear, then, that due to the high prevalence of arsenic in the environment 
and the large number of health concerns linked to arsenic exposure, the mechanism of 
toxicity warrants heavy scientific concern.  
1.3. Arsenic & Cell Signaling   
 Some of the adverse health effects of As may be linked to its ability to alter 
cellular signal transduction [13, 14]. Arsenic has been linked with the formation of 
harmful reactive oxygen species (ROS) and the disruption of tyrosine phosphorylation in 
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many cell lines and model organisms [4, 13, 14, 15, 16, 17]. Arsenic-induced ROS 
formation has been shown to cause DNA damage and protein alteration. In a study using 
AL human-hamster hybrid cells a significant increase in ROS production was observed 
within the first 5 min of exposure [20]. Furthermore, a decrease in nonprotein sulfhydryls 
caused a 5-fold increase in intragenic and multilocus deletion mutations in the DNA of 
these cells providing strong evidence for possible mechanistic routes of cancer 
development induced by arsenic [20]. Additionally, it has been well documented that As 
can have adverse effects on phosphorylation pathways [4, 13, 16, 17, 18]. For example, 
As has been linked with a significant decrease in cytokine production (IL-2) of splenic 
mononuclear cells in male mice [15]. This disruption of T-cell activation was concluded 
to be linked with an increase in the levels of phosphorylation of the early protein tyrosine 
phosphorylation cascade proteins that included Lck and Fyn kinases [15].Whether this 
effect is through the substitution of phosphate groups by the isostructural compound 
arsenate [13, 16, 18], the ability of arsenite to interact with sulfhydryl groups [13], or 
arsenite’s ability to form reactive oxygen species that inactivate kinases or phosphatases  
[13,16], or some other mechanism, it is evident that the next logical step would be to 
focus our research on the early phosphorylation events of cell signaling. 
1.4. Mast Cells & RBL-2H3 Cell Line  
 The mast cell, as a key player in parasite defense and the allergy response, is an 
important cell line to keep in mind through the evaluation of arsenic exposure and its 
effects. Mast cells, as leukocytes, play a major role in defense against pathogens and are 
derived from haematopoietic progenitor cells [8, 19, 21].  Prior to maturation within the 
mucosal and connective tissues, mast cells circulate through the vascular system as 
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progenitors following a model of development similar to that of a macrophage [8, 19]. A 
specific progenitor has only been successfully identified in fetal blood and they are 
described as expressing the cluster of differentiation (CD) molecules, CD34, CD117 (c-
kit), and CD13 in humans and Thy-1
lo
c-kit
hi
 cell in mouse [8, 22]. However, the cell 
progenitors identified in this study lacked the expression of the FcεRI receptor that is 
often associated with parasite defense, and FcεRI expression was only induced via 
experimental methods in vivo and in vitro, thus an appropriate mast cell progenitor still 
has yet to be identified [8].  
Mast cells contribute to the defense against parasites via the degranulation 
process, in which compounds meant to fight off parasitic infection are released from the 
cells’ intracellular granules.    Activation of this degranulation pathway is triggered by 
antigen, or allergen, from a foreign organism, which crosslinks IgE-bound FcεRI 
receptors, thus triggering an internal signaling pathway eventually leading to the release 
of pro-inflammatory meditators through degranulation [23, 24, 25, 26, 27]. Antigen 
stimulation sets in motion a cascade of tyrosine phosphorylation events that notably 
include the kinases Lyn and Syk [23, 24, 25, 28, 29, 30], among others. The 
phosphorylation of the receptor and the kinases leads to calcium influx and the 
mobilization and fusion of mediator-filled granules with the plasma membrane [23, 24, 
25, 28, 29]. Within these aformentioned pre-formed granules we find the mediators 
histamine, a well described player in the allergic response, tryptase and chymases 
(proteases), tumor necrosis factor-alpha and many other cytokines that are found to be 
vital in the non-specific branch of the immune system [19, 25, 23]. More detail will be 
included in the “degranulation pathway” section. 
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 The degranulation pathway has been extensively studied through the use of Rat 
Basophilic Leukemia (RBL) cells as model for basophils, due to their reliable release of 
histamine through the stimulation of FcεRI receptors [31] and their functional similarity 
to primary human basophils and rodent mast cells [32, 33]. In the literature, the RBL-2H3 
cell line has been described as sharing functional and phenotypic similarities with 
basophils and mast cells [34]. The 2H3 cell line has been shown to respond in a similar 
fashion to the calcium ionophore A23187, as do basophils and mast cells [34]. Much like 
basophils and mast cells, RBL-2H3 release β-hexosaminidase, an exoglycosidase, from 
the granules in parallel with histamine and the other mediators, which lends itself as way 
to quantify degranulation [34, 35]. The presence of Toll Like Receptor 4 (TLR4) on the 
cell surface of both RBL-2H3 and basophils attributes to their similarity; however, unlike 
basophils, RBL-2H3 are unable to respond to bacterial lipopolysaccharide membrane 
component that has been shown to interact heavily with TLR4 [34]. Furthermore, RBL-
2H3 has been shown to switch phenotypes depending on the current microenvironment in 
which they reside [34] This has been shown by Swieter et al by culturing RBL-2H3 cells 
with 3T3 fibroblast that lead to a switch from compound 48/80 insensitive RBLs to 
sensitive ones [37].Although RBLs are well accepted as models of basophils and mast 
cells, they differ in some phenotypical aspects. For example, RBL cell lines have been 
shown to express a different density of FcεRI receptors at the plasma membrane [36]. 
Given this information we have chosen to use the RBL-2H3 cell line for our investigation 
of arsenic’s effects on mast cell degranulation with the reservation that as Passante et al 
puts it, “RBL-2H3 cells resemble MMC in some respects, and display their basophilic 
lineage in others, their true nature lies somewhere in between [34].”  
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1.5. Mast Cell Degranulation 
 Activating the degranulation pathway requires the binding of an antigen, a 
molecule that elicits an immune response, to the corresponding IgE antibody. This 
antibody must first be produced by the workhouse of the immune system, the B cell. 
When an antigen enters the body it is challenged by an antigen presenting cells, most 
often a dendritic cell, which recognizes the antigen as foreign, integrates it, processes it 
and presents it via its Major Histcompatibility Complex molecule [38]. This dendritic cell 
migrates to the local lymph-node where it encounters a naïve CD4+ T-helper lymphocyte 
(TH cell) that promotes a cytokine exchange and the maturation, and differentiation, of the 
naïve TH cell to an antigen-specific TH2 cell [39].  Once activated these antigen-specific 
TH2 cell can interact with a cognate B-cell to stimulate the upregulation of CD80/CD86 
and CD40 ligands on the TH2 cell. Along with the cytokines secreted by both parties 
involved, these changes induce the B cell to proliferate into short lived plasma cells that 
immediately produce IgM antibodies. Shortly after, however, these activated B-cells 
undergo class switch recombination (stimulated by the CD40 ligation signals and the 
cytokines IL-4/IL-13) in which a complex process of rearrangement at the 
immunoglobulin heavy chain locus, and an excision and ligation of the DNA, gives rise 
to the antigen-specific IgE antibody [38]. Once the class switch recombination is 
complete, these antigen-specific B cell continue to proliferate into memory cells and the 
IgE producing plasma cells. 
 The short lived, often less than 3 days, IgE antibodies circulate the tissues to 
which they are sequestered and encounter the FcεRI receptor of an un-sensitized mast cell 
[40]. Although the FcεRI is constitutively expressed in mast cells [24, 41, 42], the high 
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affinity binding of IgE antibodies upregulates the cell-surface expression of the FcεRI 
expression and inhibits the internalization of unbound receptors on the surface [24]. The 
high affinity receptor for IgE, or FcεRI, is a membrane-bound tetrameric complex 
consisting of the IgE binding α chain, a membrane tetraspanning signal-amplifying β 
chain and the disulfide-linked homodimer γ chain that provides the signaling ability to 
the receptor [23, 24, 25, 41]. An important fact to note is that murine and human models 
differ in their β-chain requirement during receptor expression. Expression of FcεRI in 
humans can include the tetrameric form (αβγ2) or the trimeric form (αγ2) and does not 
require β chain expression for cell-surface expression like the rodent model does [43]. 
Rodent FcεRI is strictly found in its tetrameric form and the co-expression of the β-chain 
is vital for receptor expression [24, 43]. In both models, the constant (Fc) region of one 
free-floating IgE binds to the extracellular portion of a single α chain of a FcεRI receptor 
with an affinity of 1 × 10
10
 M
-1
 [43, 44].  
 Upon the 1:1 binding of IgE to FcεRI receptor, the mast cell is said to be 
sensitized [45]. A sensitized mast cell can now respond to a specific antigen by binding 
the multivalent antigen to multiple receptor-bound IgEs, causing crosslinking and 
aggregation of receptors, which initiates the signal transduction pathway leading to 
degranulation [23, 24, 45]. Aggregation of the receptors activates the protein tyrosine 
kinase (PTKs) Lyn, bound to the β chains of each receptor, which immediately goes on to 
phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAMs) of the 
receptor neighboring it; this model is known as the transphosphorylation model [46, 47]. 
There is, however, some dispute as to whether this transphosphorylation model or a lipid 
raft based model is at work. The lipid raft model claims that, upon aggregation of the 
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receptors, the aggregated receptors and Lyn (which is tethered to the plasma membrane 
via palmitoyl and myristoyl anchors) both favor and are clustered together in cholesterol- 
and saturated fat-rich, detergent resistant microdomains (DRMs).  In these small, 
specialized regions of the membrane, Lyn and the aggregated receptors are in close 
enough proximity to allow Lyn to carry out the phosphorylation of the β and γ chains of 
the receptors. In fact, Lyn is more enzymatically active inside DRMs than outside 
because of exclusion of certain phosphatases from lipid rafts [48]. 
Regardless of the model, Lyn has been shown to have a regulatory role during these early 
events. Xiao et al used BMMCs with a combination of IgE + anti-IgE, IgE+ low antigen, 
and IgE + high antigen treatments and found that the activity of Lyn as well as its 
association with FcεRI β subunit was suppressed upon low intensity stimulation, while 
high intensity stimulation caused enhanced Lyn activity and higher levels of 
phosphorylated FcεRI β subunit and Syk kinase [30].  
The ITAMs phosphorylated by Lyn consist of an 18–amino acid motif 
(E/DxxYxxLxxxxxxx-YxxL) found on the β and γ chains of each FcεRI receptors; the 
ITAMs are crucial to the initiation of the degranulation pathway [43]. Although 
activation of Lyn is agreed to be the step following receptor aggregation and eventually 
degranulation, it is not the only one. In fact, Lyn-deficient bone-marrow-derived mast 
cells showed normal degranulation suggesting a parallel, compensational pathway [49]. It 
was later determined that this complementary pathway included the PTK Fyn, known for 
maintenance and amplification of calcium (Ca
+2
) signaling [23, 24], however, in this 
study we will concentrate on the primary Lyn pathway.  
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The phosphorylation of the β and γ chains of the ITAMs by Lyn serve as docking 
sites for Src Homology 2 (SH2) domains of the PTK Syk. Syk binds to the 
phosphorylated γ chains and becomes activated, via a conformational change, after being 
phosphorylated by Lyn [31, 43]. For more information on Lyn and Syk please refer to 
their dedicated sections below. Lyn and Syk activation mark a divergence point on 
several signaling pathways that include the production of cytokines, eiscosanoids, growth 
factors and, as will be the topic of the remainder of this discussion, degranulation [24, 
Figure 1: Schematic of the Degranulation Model 
Picture was adapted from previous graphics made by Jonathan Pelletier and Rachel Kennedy. Created 
in Adobe Illustrator CS5. 
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42]. Following the degranulation pathway, activated Syk phosphorylates LAT (linker for 
activation of T cells) at four distinct residues (Y171, Y191, Y226 and Y132) that allow it 
to act as a scaffold for phospholipase Cγ1 (PLCγ1) [25, 50]. Once bound, PLCγ1 is 
phosphorylated and activated by Syk, which is followed by the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG) [25, 44]. The lipid mediator IP3 induces the release of intracellular 
stores of Ca
+2
 via the IP3 receptor (Insp3R) found on the endoplasmic reticulum 
membrane, while at the same time, DAG activates the serine/threonine protein kinase C 
(PKC) [24, 25, 51,52].  Once endoplasmatic Ca
+2
 stores are emptied, the STIM1 protein, 
a Ca
+2
 sensor found on the ER membrane, is relocated to the plasma membrane where it 
interacts with store-operated Ca
+2
 (SOC) influx via Ca
+2
- release-activated Ca
+2
 (CRAC) 
channels [53, 54]. This STIM1 protein possesses an amino-terminal EF hand Ca
+2
 
binding domain that upon depletion of ER Ca
+2
 leads to rapid translocation to the plasma 
membrane [55]. A study found that point mutations on the Ca
+2 
binding domain of 
STIM1 resulted in failure to promote SOC influx of Ca
+2
 in response to ER store 
depletion [54, 55].  Free Ca
+2
 and activated PKC act synergistically to assemble and aid 
the machinery necessary for granule fusion with the membrane. PKC has been found to 
phosphorylate both the light and heavy myosin chains, which contribute to the necessary 
rearrangement of the cortical barrier in order for vesicle fusion to occur [56, 57]. 
Furthermore, it has also been shown that Ca
+2
/Calmudulin-dependent protein kinase II 
phosphorylates also phosphorylates the heavy myosin chain during this exocytosis 
process [57, 58].  
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 Exocytosis of the mediator-filled granules requires a complex machinery to fuse 
the vesicle (granule) with the cell membrane. In mast cells this process is facilitated by 
soluble NSF (N-ethyl-maleimidesensitive factor) attachment protein receptors (SNAREs) 
that are found on the vesicle and the cell membrane [41, 59]. These SNAREs interact 
with each other to form a complex that brings both membranes to a distance that will 
allow for fusion to occur [59]. The membrane of the granule is equipped with a vesicle-
associated membrane protein (VAMP), a SNARE that has been found in many isoforms 
including VAMP 2, 3,7 or 8 [41, 60, 61]. It is not known, however, which isoform 
participates specifically during IgE mediated degranulation. The cell membrane contains 
SNAP 23, a ubiquitous SNARE, and syntaxin 4, another SNARE often associated with 
IgE mediated degranulation [41,61]. Along with these SNAREs we also see many 
accessory proteins such as NSF ATPase, for disassembly, and Rab GTPases involved in 
regulation of the complex [41, 62]. In the presence of free calcium, a calcium sensor 
(calmodulin or a synaptotagmin) binds directly to VAMP-2 and liberates it from its lipid-
bound state. Simultaneously, PKC phosphorylates SNAP 23 and syntaxin 4, which causes 
a rearrangement of cytoskeletal components that interact with the freed VAMP-2 to form 
the granule fusion complex [41, 59].  Once assembled, the presence of calcium allows for 
the vesicle and the membrane to come to a distance of 2–3 Å, which energetically favors 
the fusion of the membranes and the exocytosis of the mediators [59]. The PKC and 
DAG complex are also known to regulate phospholipase D (PLD), which plays a vital 
role in granule fusion with the cell membrane. PLD presents itself in two isoforms, PLD1 
and PLD2 that are found on the granule and the plasma membrane, respectively [63].  
1.6. Lyn Kinase 
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Lyn is a known member of the Src family of intracellular membrane-associated 
tyrosine kinases that are composed of a unique N-terminal myristoylation and 
palmitoylation site, two homologous protein interaction domains (SH2 and SH3), and a 
C-terminal kinase domain [64]. Studies have shown two important regulating residues 
located on the kinase domain:  Tyrosine (Y) residue 397, when phosphorylated, activates 
kinase activity [65] while Y508, when phosphorylated, inactives Lyn [66]. Lyn normally 
favors its inactive or closed conformation. This closed interaction is mediated through the 
negative regulatory tyrosine (Y508) at the COOH-terminus that interacts with Lyn’s own 
SH2 domain causing the protein to collapse into itself. A C-terminal Src kinase (Csk) is 
responsible for phosphorylating Y508 and keeping Lyn in its inactive conformation [66]. 
Upon FcεRI stimulation, the balance between Csk and CD45 shifts, and the phosphatase 
CD45 acts to reverse the phosphorylation of Y508 which allows Lyn’s SH2 domain to 
bind to the receptor and cause a conformational change that exposes its activation loop 
containing Y397. Phosphorylation of this residue activates the kinase activity of Lyn and 
allows Lyn to phosphorylate the receptor, and eventually Syk [67]. The role of Lyn is 
often described as a positive regulator of degranulation, but recent studies have shown 
that Lyn plays an important negative regulation role as well. Lyn has been shown to 
regulate the levels of PIP3 by inhibiting SH2 domain-containing inositol phosphatase-1 
(SHIP-1) to control the extent of degranulation [67, 68]. Lyn as also been show to inhibit 
the Fyn-dependent pathway by phosphorylating Cbp (C-terminal Src kinase (Csk)-
binding protein), allowing Csk to bind and to inhibit Fyn kinase via a mechanism similar 
to that needed to maintain Lyn’s closed conformation [67, 69]. As a kinase vital to the 
degranulation pathway, Lyn is a possible target for arsenic’s inhibitory effects.   
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1.7. Syk Kinase  
 Like Lyn, Syk is another key PTK involved in the degranulation pathway that 
could be a possible target for arsenic inhibition. Syk is part of the SYK family of tyrosine 
kinases that contain a C-terminal kinase domain and a tandem N-terminal SH2 domains 
(Figure 2 A) [50, 70, 71]. ZAP-70 and Syk, both members of the SYK family of tyrosine 
kinases, possess a linker region that separates these domains termed interdomain1, 
however, Syk has an additional 23 amino acid linker region called interdomain B that 
differentiates it from ZAP-70 [70, 71]. Due to these structural differences ZAP-70 and 
Syk have important functional differences. Syk, unlike ZAP-70, is capable of 
phosphorylating ITAMs without the help of Fyn or Lyn (Src kinases) [72]. Furthermore, 
Syk has the ability to transphosphorylate neighboring Syk molecules while ZAP-70 
requires activation via the phosphorylation of its Y493 residue by Src kinase to do so [73, 
74]; transphosphorylation is a key aspect of signal amplification. Syk, as stated above in 
the “degranulation” section, binds to phosphorylated γ chain ITAMs and becomes 
activated via a conformational change in which the linker region folds the molecule so 
that the SH2 domains are adjacent to the kinase domain. This conformation stabilizes the 
structure of Syk and exposes residues Y519 and Y520 to Lyn phosphorylation or, if Lyn 
is absent, to autophosphorylation [50, 71]. Phosphorylation of key resides Y317, Y342 
and Y346 in the linker region allows for docking, and eventually the activation, of 
downstream targets of Syk such as LAT, Vav and SLP-46 [29]. Syk is an essential kinase 
in the activation of PLCγ and Ca+2 release:  Zhang et al found that in Syk-deficient 
TBIA2  (a cell line derived from RBL-2H3 cells) cells there was no appreciable tyrosine 
phosphorylation of PLCγ1/2 and no detectable rise in intracellular Ca+2 upon receptor 
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aggregation. Furthermore, this study showed that transfection of Syk into these Syk-
deficient cells rescued the activation of PLCγ and Ca+2 influx [75]. Another study by 
Grodzki et al found that degranulation and cytokine production requires Syk as Syk 
deficient RBLs were not able to degranulate or activate NFAT (nuclear factor of 
activated T cells; transcription factors observed during Ca
+2
 fluctuations in degranulation) 
[76]. 
Figure 2: Schematic Diagram of Syk and its States of Activity 
(A) Linear structure of Syk with phosphorylated tyrosine residues mentioned in the text. (B) 
Autoinhibited structure of Syk with phosphorylated Y317 negatively regulating the activity of 
Syk. (C) Activated structure of Syk with phosphorylated Y130, Y519, and Y520, which 
positively regulate Syk. Diagrams are adopted from Figure 1 of (De Castro, 2011). Created 
using Adobe Illustrator CS5. 
A 
B 
C 
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As a vital player in degranulation, Syk is tightly regulated. Syk exists primarily in 
its autoinhibitory state that is stabilized by a hydrophobic area composed of Pro(P)-396, 
Y397 and Y474 in the kinase domain and Y319 in the linker region [77].  Upon coming 
in contact with, and binding to, the Lyn-phosphorylated γ chain of the FcεRI receptor, the 
hydrophobic interactions are disrupted, and Syk becomes activated. During the 
interaction between the SH2 domains of Syk and the phosphorylated ITAMs of the 
receptor, the residue Y130 on the linker region between the tandem SH2 domains of Syk 
plays a vital role in regulating the successful association between the two. 
Phosphorylation of Y130 dissociates Syk from the receptor by increasing the physical 
distance between the SH2 domains and preventing appropriate binding to the 
phosphorylated residues of the receptor [77]. Phosphorylation of Y317, found in 
interdomain 2, has been shown to negatively regulate Syk activity as well. In a study 
reviewed in de Castro et al, the expression of Syk-Y317F increased the activation of 
PLCγ1/2 and enhanced the degranulation of the cells; replacing Y317 with a Phe showed 
similar data as well (Figure 2 B) [77]. The positive regulation of Syk is varied and 
extensive; however, the phosphorylation of residues, via autophosphorylation or another 
kinase, Y519 and Y520 is necessary for signal transduction (Figure 2 C) [77]. 
Additionally, Zhang et al found that the replacement of either, or both, residues with Phe 
did not inhibit kinase activity, but it did hinder signal transduction as the levels of total 
tyrosine phosphorylation were considerably lower than the wild type controls [77, 78].  
Much like Lyn, Syk is an essential PTK in the degranulation pathway that is strictly 
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regulated and presents an attractive location for arsenic induced inhibition of mast cell 
degranulation.  
1.8. Current Work 
The Gosse Lab has reported on the suppressive, dose-dependent effect of As on 
mast cell degranulation at doses that are environmentally relevant [79]. They showed that 
antigen activation of the cells was necessary for As to have any effect. Second, alternate 
FcεRI cross-linking methods (other than multivalent antigen) produced similar 
degranulation and As inhibition patterns [79]; this result provides evidence that As is not 
directly disrupting the interaction between the receptor-bound IgE and the crosslinker 
(either multivalent antigen or anti-IgE antibody).  In order to assess whether arsenic’s 
effect occurs downstream or upstream of calcium influx, Hutchinson and others used 
calcium ionophore to achieve degranulation while bypassing the FcεRI receptor and the 
early tyrosine phosphorylation cascade. Their results showed that As, in fact, did not 
affect ionophore induced degranulation, and, thus, As must be affecting the signaling 
pathway somewhere upstream of calcium influx [80]. Additional evidence for a 
mechanism upstream of calcium influx was provided by Pelletier, who found that As 
does not inhibit compound 48/80-mediated degranulation, suggesting that As does not 
significantly disrupt phospholipase D activity, protein kinase C function, or the calcium 
influx process itself [81].  Taken together with Hutchinson’s calcium ionophore data, 
these data strongly suggest that arsenic’s effect in RBL cells is upstream of calcium 
influx and likely involves the phosphorylation events of key signaling molecules, such as 
Lyn or Syk kinase. 
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1.9. Piceatannol 
Piceatannol (3,4,3’5’ – tetrahydroxy-trans-stilbene) is a secondary natural product 
isolated from Euphorbia lagascae seeds [82]. It has been previously identified as an 
antileukemic compound and a protein-tyrosine phosphorylation inhibitor [82, 83, 84]. 
The structure of piceatannol is composed of a stilbene skeleton  (a trans ethene double 
bond flanked by a pair of phenyl group on both carbon atoms of the double bond; Figure 
3 A) with hydroxide substituents found on carbons 3, 3’, 4 and 5’ that have a vital role on 
its activity [81]. Using a β-hexosaminidase degranulation assay, similar to the one used in 
our lab (described in “Methods” section), Matsuda et al found that not only is 
piceatannol’s α-β double bond (Refer to Figure 3-A) important for activity, but the 
position of the oxygen-containing constituents is essential for the potency of inhibition 
[84]. Furthermore, this group found that substituting methoxyl groups in positions 3, 5’, 
and 4’ while keeping a hydroxyl group on position 3’ increased the inhibitory activity of 
piceatannol by nearly 12-fold [84].  
Figure 3: Structure of Stilbene Skeleton and Piceatannol 
(A) Structure of substituted stilbene skeleton showing the α-β bond and the positions of substituents. (B) 
Structure of piceatannol. Sources: (A) Matsuda et al, 2004 [ref] (B) Sigma-Aldrich Corportation.  
A B 
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Piceatannol’s mechanism of inhibition is still debated, but studies have shown it 
to be a competitive inhibitor of protein-tyrosine kinase activity [82, 83, 85].  In one early 
study, piceatannol isolates were incubated with p40, a protein-tyrosine kinase, and the 
catalytic subunit of cAMP-dependent protein kinase to measure its effect on enzyme 
activity. The study found that piceatannol competed with angiotensin 1 (a tyrosine-
containing peptide) for the substrate binding site of p40, but did not compete with the 
substrate for the catalytic subunit of cAMP-dependent protein-serine kinase, a peptide 
composed of Leu-Arg-Arg-Ala-Ser-Leu-Gly [82]. Geahlen et al concluded that 
piceatannol selectively inhibits protein-tyrosine kinases by competing for the substrate 
binding site through a structural resemblance to the tyrosine residue located on the 
substrate, which lended some insight into future studies involving Syk and other protein 
tyrosine kinases [82]. Years later after the discovery of Syk (also known as p72
syk
), 
Oliver et al released a study describing piceatannol as a direct inhibitor of the PTK Syk 
[83]. In this study they first found that both Lyn and Syk were inhibited by piceatannol; 
however, the difference between the IC50 for Syk and Lyn was approximately 10-fold 
with Syk being inhibited most readily [83]. Through the use of an anti-Tyr 
immunoprecipitation assay, this study also concluded that a pretreatment with 
piceatannol inhibited the tyrosine phosphorylation of Syk in a dose-dependent manner. 
Oliver et al also carried out a similar study using whole RBL-2H3 cells and found similar 
results. Additionally, these whole cell studies found that the PTK phosphorylation was 
maximal within 1-2 min of antigen stimulation, the inhibition by piceatannol occurred 
only upstream of calcium influx, and piceatannol did not inhibit the antigen-stimulated 
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phosphorylation of the receptor β and γ subunits. Finally, Oliver et al elegantly showed 
that piceatannol prevented antigen-induced ruffling and spreading (events often coupled 
to antigen stimulation of mast cells; [83]), which replicated the results of a previous study 
by Pfeiffer et al [86].  
Herein, we will attempt to elucidate if there is a relationship between the arsenic 
inhibition and the piceatannol inhibition of mast cell degranulation using a combination 
experiment. These combination experiments will provide us with more evidence as to 
whether Syk is the protein responsible for the arsenic inhibition.  
2. Materials and Methods 
2.1. Cell Culture 
All experiments were carried out using Rat Basophilic Leukemia clone 2H3 (RBL-
2H3) cells. These cells were chosen due to their robust degranulation capabilities and 
their constituent expression of FcεRI –IgE receptors (See “Introduction”). The RBL-2H3 
were obtained as a gift from D. Holowka (Cornell University, Ithaca, NY, USA).  These 
cells were maintained in a monolayer culture within sterile, tissue culture treated 
polystyrene flasks. Great care was taken to avoid plastics known to be possible sources of 
endocrine disrupting chemicals (i.e bisphenol A, polyvinyl chloride, 
polydimethylsiloxane, polyethylene terephthalate). While in culture, the cells were kept 
immersed in Eagle’s minimal essential media (EMEM, with EBSS and L-Glutamine; 
BioWhittaker Lonza) with 20% fetal bovine serum (FBS; Premium grade; Atlanta 
Biologicals) and 10 µg/mL gentamicin sulfate (BioWhittaker Lonza) to protect the cells 
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from infection. The culture conditions consisted of a constant temperature of 37°C and 
levels of CO2 of 5% within a NAPCO Series 8000 WJ CO2 incubator (Thermo 
Scientific). Flasks of cells were passed on a weekly basis using trypsin (0.05% porcine 
trypsin with EDTA in HBSS; HyClone Laboratories Inc.), for up to three months. At 
around 20 completed passages or upon the observation of undesired cell function due to 
acquired genetic mutations (gross morphological changes, major swings in degranulation 
capacity or other phenotypic changes), a new vial of cryogenically frozen RBLs was 
thawed and the previous cell stock properly discarded.  To prevent a mycoplasma 
infection, all materials coming in contact with cell culture were sterilized using 70% 
ethanol solution and all cell culture passages were carried out within a SteriGARD (The 
Baker Company) tissue culture hood periodically cleaned with 70% ethanol. 
Additionally, all buffers were sterile-filtered using Zap Cap filters (0.2 mm filter; PALL 
corporation) and a mycoplasma detection test was performed monthly using the 
MycoAlert mycoplasma detection kit (Lonza). 
2.2. Reagents and buffers 
2.2.1. Arsenic Stock Preparation 
Arsenic (As) for all experiments was prepared by Lee Hutchinson on 4/30/2011, 
as described in his thesis (Hutchinson Thesis, 2011). These stocks were concluded to be 
stable because data previously published was successfully replicated with these stocks 
(see “Results” section.) As described in Hutchinson’s graduate thesis:  “Arsenic (As) for 
all experiments was prepared under sterile conditions as 10 mM stocks of inorganic 
sodium meta-arsenite (+3 oxidation state) (Baker Analyzed, 98.0% minimum, NaAsO2, 
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CAS # 7784-46-5; JT Baker), and dissolved in cell culture water (sterile, reverse osmosis, 
deionized, distilled Water for Cell Culture Applications; BioWhittaker Lonza). It was 
next filtered with a 0.2 m syringe filter for sterility, aliquoted into sterile polypropylene 
microfuge tubes, and frozen at -20°C until day of use. No stocks were re-frozen after 
initial thawing for any experiment” [84]. 
2.2.2. Piceatannol Stock Preparation 
Piceatannol (EMD Milipore) powder was purchased as 1mg vials and dissolved in 
freshly made Tyrodes buffer. The solubility of piceatannol in water-based buffers is 0.5 
mg/mL and 10 mg/mL in DMSO and Ethanol. Piceatannol was dissolved in the water-
based Tyrode’s buffer in an effort to prevent known interference effects from the DMSO 
and ethanol.  Due to its low solubility in water, however, great care was taken to ensure 
the piceatannol was fully dissolved within the buffer. Furthermore, all experiments using 
piceatannol included a NanoDrop  Spectrophotometer (ND-1000; NanoDrop 
Technologies) UV-Vis analysis prior to use in order to obtain the most accurate 
concentration measurement. To calculate the concentration of piceatannol, a 0.1 mm path 
length was used and the absorbance at 320nm was noted. The molar extinction coefficient 
of piceatannol was calculated to be 0.045 µM
-1
 cm
-1
 from the data published by Li et al 
[87]. These stocks were frozen at -20 °C until the day of use. Manufacturer’s instructions 
of storage included storing the piceatannol stock under argon or likewise at -80°C. For 
convenience, the piceatannol stocks were made immediately before use and discarded.  
2.2.3. Tyrode’s Buffer Preparation 
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Tyrode’s buffer was used as the vehicle for piceatannol and Bovine Serum 
Albumin (BSA; Calbiochem) vehicle. It was extensively used throughout all experiments, 
so stocks of 1L were made and stored at a temperature of 4°C. This buffer contained 135 
mM NaCl (BioUltra; Sigma-Aldrich), 1.8mM CaCl2 (dihydrate; ACROS organics), 5mM 
KCl (JT Baker), 1mM MgCl2 (hexahydrate; BDH), 5.6 mM D-(+)-glucose (anhydrous; 
MP Biomedicals) and 20mM HEPES sodium salt (Ultra-pure; JT Baker). Stocks of NaCl, 
CaCl2, KCl, and MgCl2 were made to concentrations of 0.5 M or 1M and kept at 4°C for 
multiple preparations of the buffer. These stocks were dissolved using MiliQ ultra-pure 
water (Milipore) and sterilized through a bottle-top filter (Corning). The buffer was 
prepared through the combination of ingredients to their exact corresponding 
concentration, diluted using MiliQ water, and sterilized using ZapCap 0.2mm filters. The 
pH of the buffer was adjusted to 7.4 using concentrated HCl (12N; BDH Aristar). 
2.3. Degranulation Assay 
To quantify the extent of degranulation of RBL-2H3 following treatment, we used 
a β-hexosaminidase activity assay. The enzyme β-hexosaminidase (β-hex) is a natural 
product of degranulation and is released into the supernatant of culture cells. A synthetic 
substrate of β-hex, 4-methylumbelliferyl-N-acetyl-D-glucosaminide (Calbiochem), is 
cleaved to produce the fluorescent compound methylumbelliferrone that allows for a 
direct measure of degranulation [35]. A fluorescent microplate reader (BioTek Synergy 
2) was used in accordance to a previous assay as described by Naal et al [35].  
For every degranulation experiment, RBL cells were harvested 2-4 days after 
passage using a 5 min. (37°C) trypsinization treatment to dislodge the cells. Following an 
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8 min centrifugation at 500 g, the cells were resuspended at a density of 0.5 x 10 
6
 cells/ 
mL in fresh media. The cells were then plated in a black flat-bottom, tissue-culture 
treated, sterile 96-well plate (Greiner Bio-One) at a volume 100 µL per well. There 
additions were randomized to minimize systematic error. Finally, the plate was incubated 
overnight (12-16 hr.) at 5% CO2 and 37°C.  
All degranulation experiments herein included the following treatments in 
triplicates following IgE sensitization (discussed below). The addition of these treatments 
was randomized and plates were flipped accordingly to eliminate plate position effects. 
Each plate contained: (1) Antigen stimulation wells via DNP-BSA; (2) Spontaneous 
release via Tyrodes-BSA (at 1 mg/mL BSA) buffer ; (3) Total β-hex release via Triton- X 
100 (Surfact-Amps X-100, 10%, low carbonyl and peroxide; Thermo Scientific) 
detergent cell lysis; (4) Background control wells with Tyrodes-BSA buffer and no cells. 
Upon completion of the overnight incubation the spent media was discarded and 
replaced with  100µL fresh media containing 0.1 µg/mL of anti-dinitrophenyl (DNP) 
mouse IgE (monoclonal, clone SPE-7; Sigma-Aldrich). The plate was incubated for 1 
hour at 37°C and 5% CO2 to allow for sensitization of the IgE receptors. After the IgE 
sensitization, the media mixture was discarded and the plate was washed twice with 
Tyrodes-BSA buffer (BT) to remove any IgE-media remnants.  
Antigen treatments were solutions containing Tyrodes-BSA and multivalent 
DNP-BSA at the appropriate concentration. DNP-BSA antigen is BSA that has been 
conjugated  with an average of 15 dinitrophenol (DNP) groups. The DNP- BSA was 
prepared as described by Hardy et al [88] and donated by D. Holowka and B. Baird at 
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Cornell University.  Wells containing cells to be stimulated received 200 µL of the 
appropriate concentration of DNP-BSA antigen (concentrations varied depending on the 
experiment). Wells designated as spontaneous received 200 µL of BT and those 
designated as “total release” were exposed to 0.2% Triton at a volume of 200 µL. Wells 
designated as background received 200 µL of BT and were used to measure background 
fluorescence. After finalizing all additions, the plate was incubated in a cell incubator at 
5% CO2 and 37°C for 1 hour.  
After the 1 hour treatment, plates were placed on ice to halt degranulation. A 
sample of 25 µL was removed from each treated well and combined with 100 µL of 1.2 
mM β-hex substrate (4-methylumbelliferyl-N-acetyl-β-D-glucosaminide; dissolved in 
acetate buffer) in a fresh, pre-cooled 96 well plate. The acetate buffer used to dissolve the 
β-hex contains acetic acid (glacial, ACS and USP grade; BDH Aristar) at a concentration 
of 0.12 M titrated to a pH of 4.4 with sodium hydroxide (10N; JT Baker). The fresh plate 
containing the substrate and supernatants was incubated for 30 min at 37°C. At 30 min 
the reaction in the wells was quenched by adding 200 µL of cold glycine-carbonate 
buffer. The glycine-carbonate buffer contained 0.356 M glycine (Omnipur; EMD) and 
0.444 M sodium carbonate (anhydrous, granular, ACS grade) titrated to pH of 10.  
Following the 30 min incubation of the enzyme and the substrate we used a 
microplate reader (Synergy 2; Biotek) to measure the activity of β-hex. The hydrolyzed 
substate was excited using a 360/40 nm excitation filter and the fluorescence intensity 
was read using 460/40 nm emission filter at normal speed and with a sensitivity setting of 
40. Other settings included a distance of 7mm top optical offset and top 50% optics 
27 
 
position.  The raw data was processed by first subtracting the background fluorescence 
value corresponding to wells with only BT. Second, the corrected values were divided by 
the average total release (average raw fluorescence values of Triton-X 100 cell 
supernatants) to yield a percent degranulation value.  
Experiments using piceatannol included an extra step following IgE sensitization 
but preceding antigen stimulation as described by Naal et al [35]. The piceatannol step 
was a 10 minute exposure to 100 µL/well of varying piceatannol concentrations added 
immediately after two BT washes. After the 10 minute incubation the piceatannol 
treatment was discarded and the addition of 1 x 10
-3
 µg/mL DNP-BSA antigen followed. 
Appropriate piceatannol-BT and piceatannol-Spontaneous controls were used for the 
calculations of piceatannol containing treatments. These controls were necessary, because 
piceatannol was shown to have some effect on both background fluorescence and 
spontaneous release (See Results Section for more information).  
Experiments using arsenic included a modification of the antigen addition step. 
Arsenic was added into the antigen mixture prior to the addition to the plate. For the 
wells not receiving arsenic, water (As vehicle) for cell culture (ultrafiltered, reverse 
osmosis, deonized, distilled; Lonza) was added. After the addition of arsenic, or cell 
water, to the antigen treatments, each corresponding well received 200 µL of the 
appropriate treatment. 
2.4. Phospho-Syk ELISA  
The early results of piceatannol experiments provided some indirect evidence of 
the involvement of the protein-tyrosine kinase, Syk, in arsenic inhibition of degranulation 
28 
 
(See “Results” and “Discussion” sections for more information). With support from the 
literature about arsenic disrupting phosphorylation patterns, we decided to seek a more 
focused analysis of the phosphorylation of Syk under various treatments. After looking 
through our options, we decided upon a Sandwich Phospho-Syk ELISA (Figure 4).  
An ELISA, Enzyme-Linked Immunosorbent Assay, is a common biochemical 
method used to screen for a specific antibody or to quantify an antigen in a sample [89]. 
There exist many variations including indirect, direct competitive, antibody-sandwich, 
double antibody-sandwich, direct cellular, and indirect cellular ELISAs. Herein we will 
describe the protocol of the ELISA used in our experiments, an antibody-sandwich 
ELISA; for a description of the other types please see Hornbeck et al as referenced here 
[90]. An antibody-sandwich ELISA is often regarded as the most sensitive ELISA 
available with detection measurements between 2 and 5 times higher than the other types 
[90]. A typical antibody-sandwich ELISA consists of a 96-well plate coated with a 
capture antibody specific for the antigen in question. The wells are incubated with a test 
solution containing the antigen (often a whole cell lysate or a blood sample) and washed 
to remove unbound antigen. Later, a detection antibody conjugated to enzyme is added, 
which binds to the antigen in question and acts as a developing agent in later steps. The 
wells are once more washed to remove any unbound detection antibody and the addition 
of the enzyme substrate is added. This substrate is hydrolyzed by the enzyme bound to 
the detection antibody, which either fluoresces upon stimulation (fluorescent) or produces 
a color that can be measured via absorption (chromogenic). Due to the 1:1 binding, the 
extent of substrate hydrolysis as measured by a plate reader is proportional to the amount 
of antigen present in the original sample [90].  
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The PathScan® Phosho-Syk (panTyr) sandwich ELISA used in our experiments 
was acquired from Cell Signaling Technologies (CST) as a kit. This ELISA was 
manufactured to detect endogenous levels of phosphorylated Syk and included all 
necessary materials for the ELISA protocol; it is a chromogenic ELISA.  The kit included 
a Syk antibody coated 96-well plate, separated into twelve 8-well strips for individual 
experiments, the biotinylated phospho-tyrosine mouse detection antibody (primary 
detection antibody specific for phosphor-tyrosine Syk), the HRP-linked streptavidin 
(enzyme conjugated secondary antibody specific for the primary antibody), the TMB 
substrate (HRP substrate), a proprietary STOP solution, a 20X wash buffer, a proprietary 
sample diluent, a 10X cell lysis buffer (containing 20mM Tris (pH 7.5), 150mM NaCl, 
1mM EDTA, 1mM EGTA, 1% Triton X-100 [lysing detergent], 2.5mM sodium 
pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1µg/mL leupeptin) and sealing 
tape to prevent vaporization during incubation times. The kit was instructed to be stored 
at 4°C with the exception of the 10X cell lysis, which was instructed to be stored under -
20°C.  
The protocol that will follow is a modified version of the CST provided protocol. 
The lysates were extracted from whole RBL-2H3 cells passed and cared for as described 
above in the “Cell Culture” section. RBL cells were harvested 3-6 days after passage 
using a 5 min. (37°C) trypsinization treatment to dislodge the cells. Following an 8 min 
centrifugation at 500xg, the cells were resuspended at a density of 1.75 x 10
6
 cells/ mL in 
fresh media. The cells were then plated on 10cm tissue-culture treated, sterile dishes 
(Cellstar, Acquired from VWR International) at a volume of  5 mL per well (final cell 
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density of 8.75x10
6
 cells per dish). Finally, the dishes were incubated overnight (12-16 
hr.) at 5% CO2 and 37°C. 
 
Following the overnight incubation, each dish was checked to ensure a cell 
confluence between 80 and 90%. The cell media was then immediately discarded and 
replaced with fresh media containing anti-DNP IgE (Sigma) at a final concentration of 
0.1 µg/mL. The dishes were incubated for 1hr at 5% CO2 and 37°C. After the 1hr IgE-
sensitization, the spent IgE-media mixture was discarded and washed twice with 5 mL of 
BSA-Tyrodes to remove any unbound IgE. The 5 mL treatements added next included 
either BSA-Tyrodes for the unstimulated controls or DNP-BSA antigen at 1µg/mL for 
stimulated samples. The dishes were incubated for either 5 mins in a bacterial incubator 
Figure 4: Summary of ELISA protocol 
Schematic of Phospho-Syk ELISA protocol used herein. Created using Adobe Illustrator CS5 
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at 37°C. Immediately after the incubation, the dishes were removed, placed on ice, 
washed once with ice-cold PBS (4-5mL) and lysed with 0.5 mL of ice-cold 1X lysis 
buffer containing PMSF for 5 min. The 10X lysis buffer provided in the kit was thawed 
at 25°C and diluted with purified Mili-Q water before use; Phenylmethanesulfonyl 
fluoride solution (PMSF; 100mM stock dissolved in Ethanol; Sigma-Aldrich) was added 
at a concentration of 1mM immediately prior to lysis buffer addition. Following the lysis 
incubation the cells were harvested into pre-cooled 2 mL microcentrifuge tubes by using 
a sterile cell scrapper. Each lysate was then sonicated on ice by introducing a clean 
sonicating probe directly into the lysate. The sonicator was set at 35 watt output and each 
lysate was sonicated 2 times for 5 sec each time with a 10 sec break in between. Finally, 
the sonicated lysates were spun down at 14,000 x rpm for 10 min at 4°C. A volume of 
100 µL of the clear supernatants from the centrifuged samples were separated from their 
pellets and placed in new pre-cooled tubes containing 100 µL sample diluent (provided in 
the CST kit). After a brief vortex, 100 µL of the diluted sample were placed in their 
appropriate ELISA wells, sealed with tape and incubated overnight (16-20 hrs) at 4°C. 
The following day, the plate contents were discarded and each well was washed 
with 4 times with 200 µL of 1X wash buffer (20X wash buffer provided by CST was 
diluted using purified Mili-Q water). The washes were followed by an addition of 100 µL 
of the biotinylated phospho-tyrosine mouse detection antibody to each well. The plate 
was sealed and incubated at 37°C for 1hr. Following the incubation the well contents 
were discarded and each well was washed 4 times with 200 µL of 1X wash buffer. Next, 
100 µL of the HRP-linked secondary antibody were added to each well, the plate was 
sealed, and incubated at 37°C for 30 min. Once more, the contents of each well were 
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discarded and the wells were washed with 200 µL of 1X wash buffer. A volume of 100 
µL of the TMB substrate was added and the plate was sealed and incubated for 10min at 
37°C. After this 10 min incubation, and immediately before reading, 100 µL of the STOP 
solution were added to each well. An initial blue color upon addition of TMB substrate 
indicated a positive reaction, which then changed to yellow when the STOP solution was 
added. The plate was immediately placed in a BioTek Synergy 2 microplate reader and 
the absorbance of each well as measured at 450 nm.    
Experiments using arsenic included a modification of the antigen addition step. 
Arsenic was added into the antigen mixture prior to the addition to the dishes. For the 
dishes wells not receiving arsenic, water (As vehicle) for cell culture (ultrafiltered, 
reverse osmosis, deonized, distilled; Lonza) was added. After the addition of arsenic, or 
cell water, to the antigen treatments, each corresponding dishes received 5mL of the 
appropriate treatment as described in the manufacturer’s ELISA protocol. 
3. Results 
3.1. Establishment of 1 hr Piceatannol-Arsenic Combination Assay 
The piceatannol-arsenic combination assays followed the same structure as the 
arsenic experiments for which data has been previously published [79] with the exception 
of the addition of a 10 min piceatannol addition step prior to antigen stimulation [35]. In 
order to observe a possible effect of this extra step on normal mast cell degranulation 
(monitored via antigen dose response experiments) we carried out an antigen dose 
response with a 10 min mock piceatannol step. This mock-piceatannol step was a 10 
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minute exposure to 100 µL of warmed Tyrode’s Buffer added immediately after two BT 
washes. After the 10 minute incubation the mock-piceatannol treatment was discarded 
and the addition of various antigen concentrations followed. Appropriate Tyrode’s-BT 
and Tyrode’s-Spontaneous controls were used for the calculations of piceatannol 
containing treatments. The mock-piceatannol antigen dose response (Figure 5-A) elicited 
a maximal degranulation (at 0.1 µg/mL DNP-BSA antigen) of 41.16% - 46.46% (95% 
CL) and spontaneous levels of 2.3% ± 0.4 (SD), while a typical antigen dose response 
(without the extra 10 min pre-stimulation exposure; Figure 5-B) elicited a maximal 
degranulation (at 0.1 µg/mL DNP-BSA antigen) of 35.61% - 37.93% (95% CL) and 
spontaneous levels of 1.4 % ± 0.4 (SD). From these results we concluded that the 
addition of the additional 10 min exposure could be having an effect on the degranulation 
of RBLs, however, this data represents only a pair of separate experiments so conclusions 
must be made carefully. Furthermore, the maximal degranulation for the experiment 
including the mock  and the one without (41% and 38%) are similar enough as to 
conclude that if there is an effect due to this extra step, then it is a small and will likely be 
abolished by implementing the corresponding controls. It needs to be noted that 
experiments with cell culture will inherently have variation from experiment to 
experiment depending on the number of passages that have been carried out on a 
particular thaw, the day the cells are harvested, and the time the cells spend in culture 
(unpublished observations).  
Previously published data from this lab revealed that lower concentrations of 
antigen yielded the strongest arsenic dampening effect [79]. Keeping this in mind, we 
carried out several experiments involving a 10 min piceatannol mock step prior to 
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stimulation with (A) 0.00002 µg/mL, (B) 0.00004 µg/mL, and (C) 0.001 µg/mL DNP-
BSA antigen (Figure 6). Each experiment also received varying arsenic concentrations. 
Low concentrations of antigen with the 10 min mock piceatannol step resulted in 
unreliable and highly variable results, likely due to the low extent of degranulation 
observed (less than 3% degranulation). The maximal degranulation for the lower antigen 
concentrations without arsenic was at, or around, the same level as spontaneous 
degranulation. A higher antigen concentration (0.001 µg/mL) was thus chosen. The 
outcome was a replication of the arsenic inhibition pattern observed in the Hutchinson et 
al [79]. In the absence of As, the absolute level of degranulation was 26% ± 3% (SD); 
untreated cells yielded spontaneous degranulation levels of 3.1% ±0.5 (SD) (Figure 6). 
This absolute level of degranulation is comparable to the level elicited by 0.0004 µg/mL 
DNP-BSA in previously published results (Compare 26% ± 3% (SD) observed in Figure 
6 to 25% ± 1% (SD) observed in Hutchinson et al) [79]. At the highest concentration of 
arsenic of 750ppb, our experiments showed a ~31% inhibition of degranulation (Figure  
6) that is comparable to the ~37% (0.63-fold inhibition) inhibition observed in 
Hutchinson et al for experiments eliciting similar absolute levels of degranulation in the 
absence of As [79]. These results affirmed the potency of the arsenic stock, and it also 
enabled us to choose the antigen concentration that that was to be used for all piceatannol 
experiments. 
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Figure 5: Effects of 10 min Exposure Step Pre-Stimulation  
RBL cells were cultured overnight and washed twice with Tyrodes-BSA. Cells were either (A) 
exposed to warm Tyrode’s buffer for 10 minutes prior to antigen stimulation or (B) lacked this 
additional 10 min exposure step. The β-hexosaminidase release (expressed as a percentage of 
degranulation) is plotted against the log10 [DNP-BSA]. (C) is a combined plot of (A) and (B) 
with their respective 95% CI as dashed lines. Graphs are expressed as means ± SD; two 
experiments for each graph; three replicates per dose per experiment. Best fit line plotted was 
calculated using the “Sigmoidal regression (variable slope)” function in GraphPad Prism 
version 4.  
A 
B 
C 
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3.2. Effects of Piceatannol-Arsenic Co-Exposure on 1 hr DNP-BSA Mediated 
Degranulation  
An investigation of the effect of piceatannol-arsenic co-exposure was performed. 
Using varying doses of piceatannol during a 10 min pre-stimulation exposure as followed 
by a 1hr antigen ± 750ppb arsenic exposure, it was found that 200 µM piceatannol, in 
combination with arsenic, dampened degranulation by ~77%  while the exposure to 
arsenic alone produced a ~23% inhibition of degranulation (Figure 7). In the absence of 
arsenic and piceatannol, these experiments elicited an absolute level of degranulation of 
35.2% ± 3% (SD) and spontaneous levels of 5.2% ± 0.7% (SD). This absolute level of 
degranulation is comparable to the level elicited by 0.0004 µg/mL DNP-BSA in 
Figure 6: Optimization of Antigen Concentrations for 1 hr Piceatannol-Arsenic Combination 
Assays.   
RBL cells were cultured overnight and washed twice with Tyrode’s buffer. Cell were then exposed 
to warm Tyrode’s (piceatannol mock) for 10 min prior to stimulation with 0.001 µg/mL DNP-BSA 
for 1 hr. Each experiment also included a simultaneous exposure to varying doses of arsenic during 
this 1 hr stimulation period.  One way ANOVA tests were implemented and statistical significance 
when compared to 0 ppb is symbolized as ** for p-values less than 0.001.  
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previously published results (Compare 35.2% ± 3% (SD) observed in Figure 7 to 25% ± 
1% (SD) observed in Hutchinson et al) [79]. These results also fall in line with previous 
data shown in this report of 26% ± 3% (SD) (Figure 6). At the highest concentration of 
arsenic of 750ppb without piceatannol, our experiments showed an average of  ~24% 
inhibition of degranulation that is comparable to the ~37% (0.63-fold inhibition) 
inhibition observed in Hutchinson et al [79] and ~31% reported earlier in this thesis 
(Figure 6) for experiments eliciting similar absolute levels of degranulation. The arsenic 
inhibition of degranulation was consistent throughout the doses 0 µM, 20µM, and 100 
µM piceatannol (inhibitions were ~26%, ~28%, ~29% respectively), however, at 200 µM 
piceatannol this inhibition was only ~12% (Calculated based upon the change in 
inhibition [No As – As] for each piceatannol dose) (Figure 7).  In the absence of arsenic, 
the piceatannol inhibition of degranulation for doses 20µM, 100 µM, and 200 µM was 
~13%, ~37%, and ~65% respectively (Figure 7). Co-exposure to 750 ppb arsenic and 
20µM, 100 µM, and 200 µM piceatannol inhibited degranulation by ~41%, ~66%, ~77% 
respectively (Figure 7). 
Piceatannol did show some concerning effects on spontaneous degranulation, 
however. Although insignificant in the combined data, individual spontaneous results 
showed piceatannol-arsenic co-exposure induced inhibition of up to 10% that should be 
noted (Figure 8-A). All raw fluorescence values were compared to their respective 
controls (i.e piceatannol-arsenic exposures were compared to arsenic with no piceatannol 
background samples; piceatannol only exposures were compared to no arsenic-no 
piceatannol background samples) when calculating percent degranulation to avoid any 
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possible piceatannol induced interference of background fluorescence. Still, it was found 
piceatannol at 200 µM  decreasing background fluorescence by 20% when compared to 
Tyrode’s-BSA sample (Figure 8-B). 
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Figure 7: Effects of Piceatannol-Arsenic Co-Exposure on 1 hr DNP-BSA Mediated 
Degranulation 
RBL cells were cultured overnight and washed twice with Tyrode’s buffer. Cell were then exposed 
to piceatannol at the indicated doses for 10 min prior to stimulation with 0.001 µg/mL DNP-BSA 
and simultaneous exposure to 750ppb for 1 hr. (A) Combined  data,  (B) Normalized data reported in 
(A): Values were normalized to . In graphs (A) and (B) percent of degranulation is plotted against 
the concentration of piceatannol. The results of  antigen stimulated cells exposed to no arsenic and 
no piceatannol (No As, 0 uM piceatannol . (A) was evaluated using individual t-tests by comparing 
the As  to No As treatments for each piceatannol concentration.  * and *** represent p-values of less 
than 0.05 and 0.0001 respectively.   
A 
B 
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Figure 8: Effects of 200 µM Piceatannol on Spontaneous Release and Background Fluorescence 
Effects of 200 µM piceatannol on (A): Spontaneous release and (B) Background fluorescence. (A) RBL 
cells were cultured overnight and washed twice with Tyrode’s buffer. Cells were then exposed to 
piceatannol at the indicated doses for 10 min prior to BSA- Tyrode’s addition (as opposed to antigen 
stimulation). (B) Wells with no plated cells were washed twice with Tyrode’s buffer. Wells were then 
exposed either warm Tyrode’s (BT bar) or 200 µM piceatannol for 10 min prior to BSA-Tyrode’s 
exposure for 1hr. Unpaired t-tests were run to evaluate significance: ns= not significant; ***= p-value < 
0.0001.  
A 
B 
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3.3. Establishment of Phospho-Syk ELISA Experiments 
The protocol for the Phospho-Syk ELISA experiments was heavily based upon the 
reference protocol provided with the PathScan® Phosho-Syk (panTyr) kit from Cell 
Signaling Technologies. Still, many individual steps in this protocol had to be tailored to 
our system (See Figure 9 for all optimizations). The first of these steps was the sonication 
procedure.  Cells were lysed as described in the “Methods” section, scraped off the 
dishes, and sonicated at 35Watts at different time intervals. The lysates were inspected 
for live cells and counted under the microscope using trypan blue dye. Ultimately, it was 
found that sonicating the lysates at 35 Watts 3 times for 5 seconds, with 10 seconds 
breaks in between, resulted in the fastest sonication procedure to fully lyse the cells 
(results not shown). Due to the fragility of the phosphorylation state of these proteins, it 
was crucial to ensure that steps following the stimulation of the cells were carried out as 
quickly as possible. Another step that was evaluated during the development of the 
protocol was the correct dilution of the lysates and the incubation time of the STOP 
solution following the incubation of the TMB substrate. The ELISA kit provided a 
sample diluent, whose ingredients are proprietary, and recommended a 1:1 dilution of the 
processed lysate prior to addition to the ELISA plate. Using the procedure described in 
the “Methods” section, it was found that the 1:1 dilution elicited the most robust percent 
increase in antigen-stimulated Syk phosphorylation with an average percent increase over 
control (BT) of 25% for all time points (Figure 10-B). Furthermore, immediate reading of 
the sample following the addition of STOP (0 min columns; Figure 10 A-C), as compared 
to later timeframes, showed the highest percent increase in Syk phosphorylation for 
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undiluted and 1:2 diluted samples with 14.57% ± 0.93% (SD) and 17.17% respectively 
(Figure 10-A and C).  
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Parameter Tested Experimental Result Conclusion 
Cell density to be cultured in 
10cm dishes that produces 80-
90% confluence following 
overnight incubation 
Densities tested: 
11.375x10
6
 cells/dish: confluence 
falls within 80-90% 
9.625x10
6
 cells/dish: confluence 
was lower than 80% 
8.75x10
6
 cells/dish: considerably 
underconfluent 
Cells will be cultured at 
11.375x10
6
 cells per dish for 16-
20 hrs to achieve 80-90%.  
Extent of lysis following various 
[detergent] in 5 min lysis buffer 
incubation without scraping 
Tested: 
0.2% TX: low cell lysis 
0.5% TX: low cell lysis 
1% TX: moderate cell lysis 
As recommended by CST, 1% 
TX lysis buffer elicits the highest 
extent of lysis, however, scraping 
maybe be needed as there was not 
enough lysis observed 
Extent of lysis following various 
[detergent] in 5 min lysis buffer 
incubation with scraping 
Tested: 
0.2% TX: low cell lysis; almost 
undisturbed cell lawn 
0.5% TX: moderate cell lysis; 
cells looked stressed and some 
were lysed 
1% TX: high cell lysis; small 
number of viable cells observed 
The lysis procedure using a lysis 
buffer with 1% TX and scraping 
resulted in the highest extend of 
lysis 
Sonication of cell lysates that 
result in no visible whole cells or 
cellular fragments 
Tested: 
Sonicated 3 times for 5 sec each 
@ intensity of 25 W: whole cells 
obseved 
Sonicated 3 times for 10 sec each 
@ intensity of 25 W: whole cells 
observed 
Sonicated 3 times for 5 sec @ 
intensity of 35 W: no whole cells, 
some fragments 
Sonicated 3 times for 10 sec @ 
intensity of 35 W: no whole cells, 
some fragments 
 
The final sonication procedure 
was chosen to have an intensity 
of 35W repeated 3 times for 
duration of 5 secs each. This was 
chosen over the similar procedure 
at 10 sec as no difference was 
observed between these 
treatments 
Extent of dilution of cell lysate 
(immediate reading following 
STOP addition) 
Tested: 
Undiluted: 14.5% increase over 
control 
1:1 dilution: 23% increase over 
control 
1:2 dilution: 17.1% increase over 
control 
Reading immediately following 
the addition of STOP solution (as 
recommended by CST), it was 
found that a 1:1 dilution of lysate 
with the manufacturer’s diluent 
produced the highest percent 
increase  over control in phospho-
Syk  
Extent of STOP incubation time 
for 1:1 diluted lysates 
Tested: 
0 min: 23% increase over control 
5 min: 25% increase over control 
20 min: 24% increase over 
control 
Samples diluted 1:1 with the 
manufacturer’s diluent produced 
the same percent increase over 
control in phosphor-Syk 
regardless of the extent of STOP 
incubation time. Immediate 
reading was chosen as 
recommended by CST.  
Figure 9: Optimization of the Phospho-Syk ELISA Protocol 
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A 
B 
C 
Figure 10: Investigation of the Effect of Dilution and Incubation Time of the STOP Solution on 
Phosphor-Syk Phosphorylation as Measured via ELISA.   
Lysate samples were prepared as described in “Methods” Section. Each 100 µL lysate sample was added 
to the ELISA plate either (A) undiluted, (B) diluted 1:1 with sample diluent, or (C) diluted 1:2 with 
sample diluent.  Samples were plated in duplicates, with the exception of (C) which is only based on one 
sample; their error bars represent SD.  
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3.4. Investigation of the SYK Gene in Human and Rat 
The plates provided with the PathScan® Phosho-Syk (panTyr) kit from Cell 
Signaling Technologies were coated with anti- human Syk antibodies. Since the cells we 
used for our experiments were rat cells, we aimed to ensure that there would be 
appropriate cross-reactivity between the RBL cell’ rat Syk and the kit’s anti-human 
antibodies. Thus, we carried out an alignment of the SYK gene in human (Homo sapiens) 
and that of rat (Rattus norvegicus). An alignment analysis of the long human isoform 
SYK and rat SYK in ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2) using the 
default settings was carried out and resulted in 91% homology at the protein level and 
84% at the nucleotide level (Figures 11 and 12) (Juyoung Shim, unpublished analysis). 
Such high homology values allowed us to conclude that there is a high probability that 
anti-human Syk antibodies could in fact recognize rat Syk proteins. 
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MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRK 
AHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPF 
EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQ 
IVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQL 
VEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPK 
PGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRP 
KEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAE 
ANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSM 
GMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYA 
PECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPRE 
MYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN\ 
 
 
 
MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRK 
AHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPF 
EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQ 
IVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQL 
VEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPASSPAQGNRQESTVSFNPY 
EPELAPWAADKGPQREALPMDTEVYESPYADPEEIRPKEVYLDRKLLTLEDKELGSGNFG 
TVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAES 
WMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLV 
TQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMW 
EAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVE 
LRLRNYYYDVVN 
 
 
 
MAGNAVDNANHLTYFFGNITREEAEDYLVQGGMTDGLYLLRQSRNYLGGFALSVAHNRKAHHYTIERELN 
GTYAISGGRAHASPADLCHYHSQEPEGLVCLLKKPFNRPPGVQPKTGPFEDLKENLIREYVKQTWNLQGQ 
ALEQAIISQKPQLEKLIATTAHEKMPWFHGNISRDESEQTVLIGSKTNGKFLIRARDNNGSFALCLLHEG 
KVLHYRIDRDKTGKLSIPEGKKFDTLWQLVEHYSYKPDGLLRVLTVPCQKIGVQMGHPGSSNAHPVTWSP 
GGIISRIKSYSFPKPGHKKPPPPQGSRPESTVSFNPYEPTGGAWGPDRGLQREALPMDTEVYESPYADPE 
EIRPKEVYLDRKLLTLEDNELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQ 
LDNPYIVRMIGICEAESWMLVMEMAAWGPLNKYLQQNRHIKDKNIIELVHQVSMGMKYLEESNFVHRDLA 
ARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYFKFSSKSDVWSFGVLMWEAF 
SYGQKPYRGMKGSEVTAMLEKGERMGCPPGCPREMYDLMFLCWTYDVENRPGFAAVELRLRNYYYDVVN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Raw Nucleotide Sequences of Human and Rat SYK Genes 
(A) |P43405|KSYK_HUMAN Tyrosine-protein kinase SYK OS=Homo sapiens GN=SYK PE=1 
SV=1 635aa 
(B) |P43405-2|KSYK_HUMAN Isoform Short of Tyrosine-protein kinase SYK OS=Homo 
sapiens GN=SYK 612aa (Short Isoform) 
(C) |NP_036890.1| tyrosine-protein kinase SYK [Rattus norvegicus] 629aa 
 
All sequences were acquired from the National Center for Biotechnology Information (NCBI). 
A 
B 
C 
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Human           MASSGMADSANHLPFFFGNITREEAEDYLVQGGMSDGLYLLRQSRNYLGGFALSVAHGRK 60 
Rat             MAGN-AVDNANHLTYFFGNITREEAEDYLVQGGMTDGLYLLRQSRNYLGGFALSVAHNRK 59 
                **..  .*.****.:*******************:**********************.** 
 
Human           AHHYTIERELNGTYAIAGGRTHASPADLCHYHSQESDGLVCLLKKPFNRPQGVQPKTGPF 120 
Rat             AHHYTIERELNGTYAISGGRAHASPADLCHYHSQEPEGLVCLLKKPFNRPPGVQPKTGPF 119 
                ****************:***:**************.:************* ********* 
 
Human           EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGKISREESEQ 180 
Rat             EDLKENLIREYVKQTWNLQGQALEQAIISQKPQLEKLIATTAHEKMPWFHGNISRDESEQ 179 
                ***************************************************:***:**** 
 
Human           IVLIGSKTNGKFLIRARDNNGSYALCLLHEGKVLHYRIDKDKTGKLSIPEGKKFDTLWQL 240 
Rat             TVLIGSKTNGKFLIRARDNNGSFALCLLHEGKVLHYRIDRDKTGKLSIPEGKKFDTLWQL 239 
                 *********************:****************:******************** 
 
Human           VEHYSYKADGLLRVLTVPCQKIGTQGNVNFGGRPQLPGSHPATWSAGGIISRIKSYSFPK 300 
Rat             VEHYSYKPDGLLRVLTVPCQKIGVQ-----MGHPGSSNAHPVTWSPGGIISRIKSYSFPK 294 
                *******.***************.*      *:*  ..:**.***.************** 
 
Human           PGHRKSSPAQGNRQESTVSFNPYEPELAPWAADKGPQREALPMDTEVYESPYADPEEIRP 360 
Rat             PGHKKPPPPQGSRPESTVSFNPYEPTGGAWGPDRGLQREALPMDTEVYESPYADPEEIRP 354 
                ***:*..*.**.* ***********  ..*..*:* ************************ 
 
Human           KEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAE 420 
Rat             KEVYLDRKLLTLEDNELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAE 414 
                **************:********************************************* 
 
Human           ANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSM 480 
Rat             ANVMQQLDNPYIVRMIGICEAESWMLVMEMAAWGPLNKYLQQNRHIKDKNIIELVHQVSM 474 
                *******************************  ************:************** 
 
Human           GMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYA 540 
Rat             GMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYA 534 
                ************************************************************ 
 
Human           PECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPRE 600 
Rat             PECINYFKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPPGCPRE 594 
                ******:***********************************************.***** 
 
Human           MYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN 635 
Rat             MYDLMFLCWTYDVENRPGFAAVELRLRNYYYDVVN 629 
                ***** ***************************** 
         
 
 
 
 
 
 
Figure 12: Alignment of long Human Isoform SYK and rat SYK 
A multiple sequence alignment was carried out using ClustalW2 version 2.1 and the default 
settings. The yellow highlight is intended to call attention to tyrosine residues 525 and 526 
(see Introduction section for more details on these residues). 
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3.5. Effects of 750 ppb Arsenic on Syk Phosphorylation as Measured via 
Phospho-Syk ELISA  
As of the writing of this thesis, the optimization of the ELISA protocol is still a work 
in progress.  Early experiments have had promising results that may point to a pattern of 
Syk phosphorylation deficiency in the presence of arsenic. An experiment involving 
monoclonal IgE sensitized RBLs stimulated with 0.001 µg/mL DNP-BSA antigen and 
treated with 750 ppb arsenic resulted in a pattern of detectable phospho-Syk dampening. 
As shown in Figure 13A, there is a clear increase in absorbance of antigen-stimulated 
Syk phosphorylation and then the subsequent decrease likely due to As interference of 
phosphorylation of Syk. Further processing of the raw absorbance readings demonstrated 
a clear percent increase in phosphorylated Syk of 30% ± 11% (avg. error; Figure 13 B). 
When exposed to 750 ppb As, the levels of phosphorylated Syk decreased to 18% ± 5% 
(avg. error; Figure 13 B), which indicates a decrease of ~42% Syk phosphorylation likely 
induced by As. However, a one-tailed unpaired t-test carried out with GraphPad Prism 
showed no statistical significance with a p-value of 0.1801.  
As stated earlier, the fragility of phosphorylated proteins requires a swift management 
and implementation of stimulation and lysis steps. It is these steps that we suspect to be 
the culprit to the inconsistency in the data and so further optimization of these steps must 
be carried out before they can produce reliable data. During these optimization 
experiments, it was proposed that the old arsenic stock could have lost its potency over 
time (stocks were originally made in 04/30/2011 by Lee Hutchinson). New stocks were 
thus prepared and their potency was evaluated (Figure 14). At antigen concentrations of 
0.0004 µg/mL (Figure 14-A) and 0.00016 µg/mL (Figure 14-B), the maximal 
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degranulation values (0 ppb As) were 145% ± 1 (SD) and 6.0% ± 0.8% (SD), 
respectively, and spontaneous degranulation levels of 7% ± 1% (SD). The maximal 
inhibition elicited by 750 ppb arsenic was ~37% and ~44%, respectively. Spontaneous 
degranulation was not affected by arsenic (Figure 14-C). These results resemble those 
published in Hutchinson et al by exhibiting a similar dose response inhibition pattern, so 
the potency of the new arsenic stock was confirmed. 
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Figure 13: Effects of 750 ppb Arsenic on Phosphorylated Syk as Measured via Phosho-Syk 
(panTyr) Sandwich ELISA 
Effects of 750 ppb Arsenic on Phosphorylated Syk as Measured via PathScan® Phosho-Syk 
(panTyr) sandwich ELISA from Cell Signaling Tech. RBL cells were stimulated with 0.001 
µg/mL DNP-BSA antigen and simultaneously treated with 750 ppb As for one hour. Cells were 
then lysed and diluted 1:1 with sample diluent prior to being added to the ELISA plate. For the 
complete ELISA protocol see the “Methods” section. (A) Raw absorbance values of Spontaneous 
(BT; non-stimulated), antigen only, and antigen and arsenic were done in duplicate; Error bars 
show average error. (B) Percent increase of antigen and antigen & arsenic treatments, over the 
non-stimulated spontaneous control. (B) is the processed form of the data shown in (A).   
A 
B 
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A 
B 
C 
Figure 14: Investigation of New Arsenic Stock Potency 
RBL cells were cultured overnight and washed twice with Tyrode’s buffer. Cells were then stimulated 
with (A) 0.0004 µg/mL, (B) 0.00016 µg/mL, and (C) Tyrode’s buffer (for spontaneous degranulation). 
Experiments were in done in triplicates; error bars signify ± SD. 
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4. Discussion 
4.1. Discussion of Piceatannol-Arsenic Co-Exposure on 1 hr DNP-BSA Mediated 
Degranulation Experiments 
While establishing the piceatannol-arsenic combination assay it was found that the 
additional 10-min step needed to expose the cell to piceatannol could be having an effect 
on the typical degranulation of RBLs. It must kept in mind that these conclusions were 
drawn from only two experiments done on different days and using cells that, although 
were from the same thaw, were not from the same passage. Still, as it is a commended 
research practice, the controls used to analyze all data included this extra step regardless 
of whether the effect is real or just an artifact. This meant that spontaneous wells, 
background wells, and TX-lysis wells all included this additional 10 min piceatannol 
exposure. Furthermore, the results from the optimization experiments of the antigen 
concentration, which included the extra 10 min piceatannol mock step, helped to ease our 
initial concerns. The 0.001 µg/mL concentration of DNP-BSA experiments (Figure 6-C) 
that exhibited an absolute level of degranulation of 26% ± 3% (SD) in the absence of As 
showed a comparable inhibition pattern shown in Hutchinson et al [79]. Additionally, and 
more importantly, the maximal inhibition at this concentration (elicited by 750ppb) was 
comparable to the inhibition elicited by the same exposure to arsenic at 0.0004 µg/mL 
DNP-BSA antigen. These experiments can be compared, because their absolute levels of 
degranulation reached a similar degree (compare 26% ± 3% (SD) observed in Figure 6to 
25% ± 1% (SD) observed in Hutchinson et al) [79]. In that same publication, these 
experiments with comparable levels of absolute degranulation experienced a maximum 
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degree of arsenic-induced inhibition of degranulation at 750 ppb with ~37% (0.63-fold) 
inhibition when compared to its appropriate 0 ppb samples [79]. Likewise, our 
experiments reported here showed a ~31% inhibition of degranulation (Figure 6) that is 
comparable to those experiments mentioned above. These results assured us that the 
potency of our arsenic stock was still at the desired level, and that an antigen 
concentration of 0.001 µg/mL elicited a level of absolute degranulation for this particular 
thaw of cells that is comparable to already published data. Furthermore, we concluded 
then that, by controlling any possible effect of the extra 10 min exposure, we could 
replicate the previously reported arsenic dose response inhibition of degranulation and 
thus our piceatannol-arsenic combination assays could be accurately used to investigate 
the possibility of arsenics involvement in the early tyrosine phosphorylation pathway.  
The addition of piceatannol to our arsenic experiments showed a robust and clear 
inhibition of degranulation. This potent combined inhibition of ~77% at arsenic 
concentrations of 750 ppb and exposure to 200 µM piceatannol for the piceatannol-
arsenic combination assays appears to point to an additive mechanism of inhibition. 
Exposure to arsenic alone produced an average of ~24% inhibition of degranulation 
(Figure 7 A andB) while piceatannol, the absence of arsenic, produced a maximal 
inhibition of degranulation of ~65%. Since only a dose of 750 ppb arsenic was used in 
these combination experiments, it was expected for arsenic to inhibit all samples equally. 
This was the case for 3 out of the 4 treatments groups. At 200 µM piceatannol and 750 
ppb As, arsenic only attributed ~12% of the inhibition while at all other piceatannol doses 
the arsenic inhibition remained at constant levels (compare ~12% at 200 µM and 750 ppb 
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As to ~26%, ~28%, ~29% at 0 µM (and 750 pbb As), 20µM (and 750 ppb As), and 100 
µM (and 750 ppb As) piceatannol respectively) (Figure 7). We suspect that the low levels 
of degranulation of cells treated with 200 µM and 750 ppb As could be help culprit to this 
erratic behavior. Cells exposed to this treatment elicited degranulation of 8% ± 1% (SD) 
(Figure 7), which is along spontaneous levels reported as 5% ± 1% (SD) for these 
experiments (spontaneous data not shown). At such low levels, it has been observed that 
degranulation patterns become erratic and unpredictable, which could explain why the 
arsenic contributions to inhibition at such high levels of piceatannol deviate from the 
other treatments (unpublished observations). In the absence of arsenic, the piceatannol 
inhibition contributed to the inhibition of degranulation in a dose dependent manner. 
Doses of piceatannol of 20µM, 100 µM, and 200 µM (confirmed using UV-Vis analysis; 
see Results section) resulted in ~13%, ~37%, and ~65%, respectively, inhibition of 
degranulation (Figure 7).  
Co-exposure to 750 ppb arsenic and 20µM, 100 µM, and 200 µM piceatannol 
inhibited degranulation by ~41%, ~66%, ~77% respectively (Figure 7). This inhibition 
occurred in an additive fashion with 750ppb arsenic contributing a consistent inhibition 
of ~24% (with the exception of 200 µM) and piceatannol contributing the rest. This 
additive inhibition of degranulation could point to a few possible mechanisms of action. 
Since piceatannol acts directly at the substrate binding site of Syk to inhibit it [83, 84] it 
is possible that arsenic could be doing the same. Arsenate, as previously stated, has been 
shown to compete with free phosphate uptake and binding during phosphorylation 
reactions [13, 16, 18, 91, 92, 93], which lends support to a mechanism in which 
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piceatannol and arsenic could be collectively inhibiting Syk by competing for the tyrosine 
binding site of phosphate. Alternatively, it is possible that while piceatannol blocks the 
binding of phosphate to these tyrosine residues, arsenic could be interfering with the 
uptake of free-phosphate by the cell. Finally, it is also possible that arsenic could be 
acting indirectly to inhibit Syk by stimulating the production of ROS, which are 
detrimental for the activity of kinases [14]. 
4.2. Discussion of the Phospho-Syk ELISA Experiments 
Optimization of the Phospho-Syk ELISA protocol has proven to be laborious, yet 
insightful process for our lab. We were able to eliminate our old arsenic stock as being a 
possible source of error, as the freshly made stock inhibited degranulation in a similar 
fashion as previously published data [79] and previous data reported here (Figure 4). The 
analysis of the human and rat SYK genes also provided valuable insight while 
eliminating a possible source of error in the optimization of our experiments. The high 
degree of homology between these genes, and the proteins they produced, made us 
confident that anti-human Syk antibodies would likely recognize rat Syk with a 
comparable degree of affinity. 
The results of other optimization procedures are summarized in Figure 9 and will be 
further discussed here. An initial parameter tested, prior to acquisition of the CST ELISA 
kit, was to optimize the density of cells to be cultured the night before the experiments. 
The target confluence of these dishes was to be between 80-90% as recommended by the 
manufacturers of the ELISA kit and the densities tested were scaled up from our own 
experiments on 96-well microplates. Upon microscope inspection of various replicated 
dishes, it was concluded that cells were to be cultured at 11.375x10
6
 cells per dish and 
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incubated overnight prior to harvesting for the ELISA experiments. The concentration of 
the detergent in our lysis buffers was also evaluated and optimized. Although the kit 
included a lysis buffer, we decided to test lower concentrations of the lysis detergent TX-
100 in an effort to disturb the fragile phosphorylation events that we being targeted. It 
was found that the combination of scrapping and a 1% TX concentration found the 
manufacturers lysis buffer) of lysis buffer was crucial for proper cell lysis. The 
recommendations of the manufacturer were then followed in this regard as they produced 
the most substantial lysis of the treated cells.  
Optimization of the protocol included within, however, is far from complete. Our 
group suspects that the sensitization, stimulation, and exposure steps (the most sensitive 
steps of the procedure) are likely to be the source of variability in our data. Our first issue 
with the optimization of these steps was the sensitization of our cultured cells. For most 
other experiments we are accustomed to using monoclonal anti-DNP IgE antibodies over 
the period of one hour immediately after the cells have cultured overnight. These 
antibodies are manufactured by Sigma-Aldrich and have had a tendency to cluster during 
long incubation times (unpublished observation). As we continue to optimize our 
experiments we are worried that these antibodies are not sensitizing cells properly and 
thus depriving the full extent of degranulation when they are stimulated. A possible 
solution to this issue has been proposed, and is currently in the process of being 
implemented. The Baird-Holowka lab (Cornell University, Ithaca, NY, USA) has kindly 
donated a stock of in-house produced and purified anti-DNP IgE antibodies that do not 
exhibit the aggregation issues of the Sigma IgE. These antibodies will enable for the 
sensitization to occur overnight, as it is often recommended when sensitizing RBLs, and 
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perhaps maximize the chances of catching a glimpse into the short lived window of 
phosphorylation of these vital PTKs. 
A second possible source of variability in our data refers to the time and procedure 
involving the stimulation of the cells with DNP-BSA. Several publications argued that 
Syk phosphorylation was maximal upon 2 min stimulation with antigen and decreased 
significantly thereafter [74, 82, 83]. We carried out a pair of ELISA experiments to verify 
these finding with stimulation times of 2 min and 5 min but the resulting the data 
contradicted itself (data not shown). In the end we concluded we would continue using 
the 5 min stimulation as it exhibited the largest percentage increase over spontaneous in 
the majority of experiments carried out thereafter. This part of the protocol is of vital 
importance and more effort should be taken to optimize the incubation time of 
stimulation.  
A third possible source of error in our Phospho-Syk ELISA protocol is the lysis 
procedure that occurs immediately after stimulation. Upon the crosslinking of the 
receptors and the recruitment of the PTKs there is a rapid phosphorylation of these PTKs 
that helps in propagation and enhancement of the stimulation signal. Almost immediately 
upon the activation of these PTKs, proteases and phosphatases begin dephosphorylating 
these PTKs to return them to their original inactivated state (see Introduction for more 
details). In an effort to conserve the phosphorylated state of Syk, our lysis buffer contains 
many anti-phosphatases and anti-proteases such as sodium orthovanadate (protein 
tyrosine phosphatases inhibitor), β-glycerophosphate (serine-threonine phosphatase 
inhibitor), leupeptin (inhibitor of serine and cysteine proteases), sodium pyrophosphate  
(Ser/Thr phosphatase inhibitor). Along with these vital components in the buffer, it was 
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also advised by the manufacturing company that all lysis steps are carried out promptly 
and at “ice-cold” conditions as to preserve the phosphorylated proteins. Within this 
crucial handling of the lysates we encounter the sonication step of cells scraped off the 
bottom of the treatment dishes. This sonication procedure provided many issues in terms 
of timing, loss of lysate volume due to splashing or excessive bubbling, and the sample 
heating from repetitive sonication. The latter issues were resolved by switching to more 
voluminous tubes and maintaining these lysate tubes submerged in a water-ice slurry 
during the whole sonication procedure. The issue of the timing, however, remained an 
elusive issue that we attempted to address. It was concluded that that sonicating the 
lysates at 35 Watts 3 times for 5 seconds with 10 seconds breaks in between resulted in 
the fastest sonication procedure that resulted in full cell lysis (Figure 9). These changes, 
as well as an acquired expertise with the protocol, have resulted in improved data yields 
that allowed us to make preliminary conclusions about the possible mechanism of arsenic 
toxicity in mast cell degranulation. 
Preliminary data from the ELISA experiments yielded promising results. In the 
presence of 750 ppb arsenic, there was an observed decrease in the phosphorylation of 
Syk as measured by our ELISA. This experiment included two biological controls per 
treatment as well as a third procedural repeat for both antigen stimulated samples and the 
spontaneous control samples. It is difficult to make conclusions with much confidence as 
these results showed a high variability amongst the samples and was unable to reach 
statistical significance at any considerable level. However, as preliminary results they are 
promising and could provide some insight into the mechanism of mast cell inhibition by 
arsenic. If these results can be replicated, then we could potentially conclude that As is 
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inhibiting degranulation by interfering with the phosphorylation of Syk. Possible 
mechanisms for this interference could be direct as is the case with the isostructural 
competition of arsenate with free-phosphate as discussed in the discussion of the 
combined piceatannol-arsenic assays and reported across many model organisms 
[13,14,16, 92]. Another direct way in which As could be acting is by interacting with 
sulfydryl groups of proteins. A study found that arsenite interacted with sulfhydryl 
groups of certain proteins, causing detrimental structural modification or denaturation 
[92, 92, 94].  These structural modifications, as reported by Akter et al, can be a vital 
source of protein inactivation across many organisms [95]. Since both human and rat Syk 
contain numerous cysteine residues, five of which are located specifically in its kinase 
domain, inactivation via sulfhydryl interaction is a realistic possibility that should be 
considered (Figure 12). Our data from the piceatannol-arsenic combination assays 
presented above, as well as the preliminary ELISA results, appear to point towards a 
more direct mode of action for arsenic-induced inhibition of degranulation. Since arsenic 
was found to have an additive effect with piceatannol and a possible specific interference 
in Syk phosphorylation, it is possible that As could be inhibiting Syk by directly blocking 
the sites of Syk phosphorylation or by inactivating Syk altogether through structural 
modifications caused by sulfhydryl interactions.  
There still exists the possibility that arsenic could be acting indirectly to inhibit Syk. 
As previously stated, arsenic could also be inhibiting the phosphorylation of Syk 
indirectly through the stimulation of oxyradical production [13, 16, 20, 93]. These ROS, 
primarily found to be superoxide, hydroxyl radicals and H2O2, have been correlated with 
damaging amino acids, purine nucleotides, nucleic acids, and proteins [93].  It is possible 
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that arsenic could be stimulating the production of these harmful radicals and thus the 
inactivation of not just Syk but many other molecules in the periphery. More experiments 
will need to be carried out before a mechanism of arsenic-induced inhibition can be 
elucidated.  
The implications of these results can help researchers better understand the mode of 
arsenic toxicity that is likely to not be organism specific. If arsenic, in fact, does inhibit 
Syk in a direct manner, then it is possible that it may be inhibiting other similar 
molecules in the same manner. Furthermore, since arsenic has already been shown to 
inhibit such a vital pathway in allergy and asthma development, then it is possible for Syk 
to be used a drug target to treat these diseases. By pharmacologically mimicking the 
effect of arsenic on Syk, in theory, it could be possible to develop a drug to inhibit the 
degranulation of mast cells and perhaps alleviate the burden that hypersensitive continues 
to have in developed countries.  
 
 
 
 
 
 
 
 
61 
 
5. References  
 
1. Gomez-Caminero  A, Howe P, Hughes M, Kenyon E, Lewis DR, Moore M, Ng J, 
Aitio A, Becking G. 2001. Environmental Health Criteria 224 Arsenic and Arsenic 
Compounds. World Health Organization Geneva. Second edition. 
2. Onishi H.1969. Arsenic. In: Wedepohl KH ed. Handbook of Geochemistry, Vol. II-
2. New York, Springer. 
3. Boyle RW, Jonasson IR. 1973. The Geochemistry Of Arsenic and its Use as an 
Indicator Element in Geochemical Prospecting. J Geochem Explor 2: 251–296. 
4. Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, Dudek EJ. 
1999. Low Levels of Arsenic Trioxide Stimulate Proliferative Signals in Primary 
Vascular Cells without Activating Stress Effector Pathways. Toxicol Appl 
Pharmacol 159: 65-75. 
5. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed 
W, Wang C, Cullen WR, Thomas DJ. 2000. Comparative Toxicity of Trivalent and 
Pentavelent Inorganic and Methylated Arsenicals in Rat and Human Cells. Arch 
Toxicol 74: 289-299. 
6. Chou S, Harper C, Ingerman L, Llados F., Colman J, Chappell L, Osier M, 
Odin M, Sage G. 2007. Toxicological Profile for Arsenic. Agency for Toxic 
Substances and Disease Registry: Atlanta, GA. 
7. Chen SL, Dzeng SR, Yang MH, Chiu KH, Shieh GM,  Wai CM. 1994. Arsenic 
Species in Groundwaters of the Blackfoot Disease Area, Taiwan. Environ Sci 
Technol 28(5):877−881. 
8. Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ. 2005. Identification 
of Mast Cell Progenitors in Adult Mice. PNAS 102 (32): 11408–11413. 
9. Wong WWK, Chung  SWC, Chan BTP, Ho YY, Xiao Y. 2013. Dietary Exposure to 
Inorganic Arsenic of the Hong Kong Population: Results of the First Hong Kong 
Total Diet Study. Food Chem Toxicol 51: 379-385. 
10. Consumer Report Magazine. 2012. Arsenic in your food; Our findings show a real 
need for federal standards for this toxin. Consumer Report Magazine. November 
2012 issue. 
11. Ratnaike RN. 2003. Acute and Chronic Arsenic Toxicity. Postgrad. Med. J. 79: 
391-396. 
12. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, 
Duggan HM, Wood R, Kosnett MJ, Smith MT. 1992. Cancer Risks from Arsenic 
in Drinking Water. Environmental Health Perspectives. 97: 259-267. 
62 
 
13. Qian Y, Castranova V, Shi X. 2003. New Perspectives in Arsenic-Induced Cell 
Signal Transduction. Journal of Inorganic Biochemistry. 96: 271-278. 
14. Druwe IL, Vaillancourt RR. 2010. Influence of Arsenate and Arsenite on Signal 
Transduction Pathways: an Update. Arch Toxicol. 84: 585-596.  
15. Soto-Peña GA, Vega L. 2008. Arsenic Interferes with the Signaling Transduction 
Pathway of T-cell Receptor Activation by Increasing Basal and Induced 
Phosphorylation of Lck and Fyn in Spleen Cells. Toxicology and Applied 
Pharmacology. 230 (2): 216-226. 
16. Ventura-Lima J, Bogo MR, Monserrat JM. 2011. Arsenic Toxicity in Mammals 
and Aquatic Animals: A Comparative Biochemical Approach. Ecotoxicology and 
Environmental Safety. 74: 211-218. 
17. Antoine F, Ennaciri J, Girard D. 2010. Syk is a Novel Target of Arsenic Trioxide 
(ATO) and is Involved in the Toxic Effect of ATO in Human Neutrophils. 
Toxicology in Vitro. 24: 936-941. 
18. DeMaster EG, Mitchell RA. 1973. A Comparison of Arsenate and Vanadate as 
Inhibitors or Uncouplers of Mitochondrial and Glycolytic Energy Metabolism. 
Biochemistry. 12 (19): 3616-3621. 
19. Urb M, Sheppard DC. 2012. The Role of Mast Cells in the Defense Against 
Pathogens. PLoS Pathog 8(4): e1002619. doi:10.1371/journal.-ppat.1002619 
20. Liu SX, Athar M, Lippai I, Waldren C, Hei TK. 2001. Induction of Oxyradicals 
by Arsenic: Implication for Mechanism of Genotoxicity. PNAS. 98 (4): 1643-1648. 
21. Kitamura Y, Shimada M, Hatanaka K, Miyano Y. 1977. Development of Mast 
Cells from Grafted Bone Marrow Cells in Irradiated Mice. Nature. 268 (5619): 442-
443. 
22. Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F. 2003. Mast Cells in 
Allergy and Beyond. The International Journal of Biochemistry & Cell Biology. 35: 
1601–1607 
23. Rivera J, Olivera A. 2008. A Current Understanding of FcεRI-Dependent Mast Cell 
Activation. Current Allergy and Asthma Reports. 8: 14-20. 
24. Kraft S, Kinet J. 2007. New Developments in FcεRI Regulation, Function and 
Inhibition. Nature Reviews: Immunology. 7: 365-378. 
25. Kopeć A, Panaszek B, Fal AM. 2006. Intracellular Signaling Pathways in IgE-
Dependent Mast Cell Activation. Arch. Immunol. Ther. Exp. 54: 393-401. 
26. Wesolowski J, Paumet F. 2011. The Impact of Bacterial Infection on Mast Cell 
Degranulation. Immunol. Res. 51: 215-226.  
63 
 
27. Amin K. 2012. The Role of Mast Cells in Allergic Inflammation. Respiratory 
Medicine. 106: 9-14. 
28. Bugajev V, Bambousková M, Dráberová L, Dráber P. 2010. What Precedes the 
Initial Tyrosine Phosphorylation of the High Affinity IgE Receptor in Antigen-
Activated Mast Cell? FEBS letters. 584: 4949-4966. 
29. Sanderson MP, Wex E, Kono T, Uto K, Schnapp A. 2010. Syk and Lyn Mediate 
Distinct Syk Phosphorylation Events in FcεRI- Signal Transduction: Implications for 
Regulation of IgE-Mediated Degranulation. Molecular Immunology. 48: 171-178. 
30. Xiao W, Nishimoto H, Hong H, Kitaura J, Nunomura S, Maeda-Yamamoto M, 
Kawakami Y, Lowell C, Chisei R, Kawakami T. 2005. Positive and Negative 
Regulation of Mast Cell Activation by Lyn via the FcεRI. The Journal of 
Immunology. 175: 6885-6892. 
31. Siraganian RP, McGivney A, Barsumian EL, Crews FT, Hirata  F, Axelrod J. 
1982. Variants of the Rat Basophilic Leukemia Cell Line for the Study of Histamine 
Release. Fed Proc. 41: 30-34. 
32. Fewtrell C, Kessler A, Metzger H. 1979. Comparative Aspects of Secretion from 
Tumor and Normal Mast Cells. Adv. Inflamm. Res. 1: 205–221. 
33. Metzger H, Alcaraz G, Hohman R, Kinet JP, Pribluda V, Quarto R. 1986. The 
Receptor with High-Affinity for Immunoglobulin-E. Annu. Rev. Immunol. 4: 419–
470. 
34. Passante E, Ehrhardt C, Sheridan H, Frankish N. 2009. RBL-2H3 Cells are an 
Imprecise Model for Mast Cell Mediator Release. Inflammation Research: Official 
Journal of The European Histamine Research Society ... [Et Al.]. 58:611-618. 
35. Naal RMZG, Tabb J, Holowka D, Baird B. 2004. In Situ Measurement of 
Degranulation as a Biosensor Based on RBL-2H3 Mast Cells. Biosensors and 
Bioelectronics. 20: 791–796 
36. Froese A, Helm RM, Conrad DH, Isersky C, Ishizaka T, Kulczycki A. 1981. 
Immunology. 46: 107-116. 
37. Swieter M, Midura RJ, Nishikata H, Oliver C, Berenstein EH, Mergenhagen 
SE, Hascall VC, Siraganian RP. 1993. Mouse 3T3 Fibroblasts Induce Rat 
Basophilic Leukemia (RBL-2H3) Cells to Acquire Responsiveness to Compound 
48/80. Journal of Immunology. 150: 617-624. 
38. Poulsen LK, Hummelshoj L. 2007. Triggers of IgE class Switching and Allergy 
Development. Annals of Medicine. 39: 440-456. 
39. Samitas K, Lötvall J, Bossios A. 2010. B Cells: From Early Development to 
Regulating Allergic Diseases. Arch. Immunol. Ther. Exp. 58: 209-225. 
64 
 
40. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, 
Smurthwaite L. 2003. The Biology of IgE And The Basis Of Allergic Disease. 21: 
579-628. 
41. Blank U, Rivera J. 2004 The Ins and Outs of IgE-Dependent Mast-Cell Exocytosis. 
TRENDS in Immunology. 25 (5): 266-273. 
42. Kawakami T, Galli SJ. 2002. Regulation of Mast-Cell and Basophil Function and 
Survival by IgE. Nature Reviews. 2: 773-786. 
43. Kinet J. 1999. The High-affinity IgE Receptor (FcεRI): From Physiology to 
Pathology. Annu. Rev. Immunol. 17: 931-972. 
44. Turner H, Kinet J. 1999. Signalling Through the High-Affinity IgE Receptor 
FcεRI. Nature. 402: 24-30. 
45. Kuby J. 1997. Immunology. W. H. Freeman and Company: New York. 
46. Okayama Y, Kashiwakura JI, Matsuda A, Sasaki-Sakamoto T, Nunomura S, 
Yokoi N, Ebihara N, Kuroda K, Ohmori K, Saito H, Ra C. 2012. The Interaction 
Between Lyn and Fcεriβ is Indispensable for Fcεri-Mediated Human Mast Cell 
Activation. Allergy. 67: 1241-1249. 
47. Pribluda VS, Pribluda C, Metzger H. 1994. Transphosphorylation as the 
Mechanism by which the High-Affinity Receptor for IgE is Phosphorylated Upon 
Aggregation. Pro. Natl. Acad. Sci. 91: 11246-11250. 
48. Young RM, Zheng X, Holowka D, Baird B. 2004. Reconstitution of Regulated 
Phosphorylation of Fcepsilon RI by a Lipid Raft-Excluded Protein Tyrosine 
Phosphatase. J Biol Chem. 280 (2): 1230-1235. 
 
49. Nishizumi H, Yamamoto T. 1997. Impaired Tyrosine Phosphorylation and Ca2+ 
Mobilization, but Not Degranulation, in Lyn-Deficient Bone Marrow-Derived Mast 
Cells. Journal of Immunology. 97: 2350-2355. 
50. Zhang W, Trible RP, Zhu M, Liu SK, McGlade J, Samelson LE. 2000. 
Association of Grb2, Gads, and Phospholipase C-g1 with Phosphorylated LAT 
Tyrosine Residues. Journal of Biological Chemistry. 275 (30): 23355-23361. 
51. Kozak JA, Kerschbaum HH, Cahalan MD. 2002. Distinct Properties of CRAC 
and MIC Channels in RBL Cells. J Gen Physiol. 120 (2): 221-235. 
 
52. Hoth M, Penner R. 1992. Depletion of intracellular calciumstores activates a 
calcium current in mast cells. Nature. 355:353–356. 
 
53. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, Safrina 
O, Kozak JA, Wagner SL, Cahalan MD, Veliçelebi G, Stauderman KA. 2005. 
65 
 
STIM1, an Essential and Conserved Component of Store-Operated Ca
2+
 Channel 
Function. J Cell Biol. 169 (3): 435-445. 
54. Baba Y, Nishida K, Fujii Y, Hirano T, Hikida M, Kurosaki T. 2008. Essential 
Function for the Calcium Sensor STIM1 in Mast Cell Activation and Anaphylactic 
Responses. Nat Immunol. 9 (1): 81-88. 
 
55. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE Jr, Meyer T. 2005. 
STIM is a Ca2+ Sensor Essential for Ca2+-Store-Depletion-Triggered Ca2+ Influx. 
Curr Biol. 15 (13): 1235-1241. 
 
56. Ludowyke RI, Peleg I, Beaven MA, Adelstein RS. 1989. Antigen-Induced 
Secretion of Histamine and the Phosphorylation of Myosin by Protein Kinase C in 
Rat Basophilic Leukemia Cells. J Biol Chem. 264(21): 12492-12501. 
57. Holst J, Sim AT, Ludowyke RI. 2002. Protein Phosphatases 1 and 2A Transiently 
Associate with Myosin During the Peak Rate of Secretion from Mast Cells. Mol Biol 
Cell. 13(3): 1083-1098.  
58. Buxton DB, Adelstein RS. 2000. Calcium-Dependent Threonine Phosphorylation of 
Nonmuscle Myosin in Stimulated RBL-2H3 Mast Cells. J Biol Chem. 275(44): 
34772-34779. 
 
59. Jena BP. 2011. Role of SNAREs in Membrane Fusion. Adv Exp Med Biol. 713: 13-
32. 
60. Tadokoro S, Nakanishi M, Hirashima N. 2010. Complexin II Regulates 
Degranulation in RBL-2H3 Cells by Interacting with SNARE Complex Containing 
Syntaxin-3. Cell Immunol. 261(1): 51-56. 
61. Woska JR Jr, Gillespie ME. 2011. Small-Interfering RNA-Mediated Identification 
and Regulation of the Ternary SNARE Complex Mediating RBL-2H3 Mast Cell 
Degranulation. Scand J Immunol. 73(1): 8-17. 
62. Epp N, Rethmeier R, Kramer L, Ungermann C. 2011. Membrane Dynamics and 
Fusion at Late Endosomes and Vacuoles- Rab Regulation, Multisubunit Tethering 
Complexes and SNAREs. Eur J Cell Biol. 90 (9): 779-785. 
63. Choi WS, Kim YM, Combs C, Frohman MA, Beaven MA. 2002. Phospholipases 
D1 and D2 Regulate Different Phases of Exocytosis in Mast Cells.  J. Immunol. 168: 
5682-5689. 
64. Ingley E. 2012. Functions of the Lyn Tyrosine Kinase in Health and Disease. Cell 
Communication and Signalling. 10: 21-32. 
65. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. 1999. Crystal Structures of c-Src 
Reveal Features of its Autoinhibitory Mechanism. Molecular Cell. 3: 629-638. 
66 
 
66. Futami M, Zhu QS, Whichard ZL, Xia L, Ke Y, Neel BG, Feng GS, Corey SJ 
2011. G-CSF Receptor Activation of the Scr Kinase Lyn is Mediated by Gab2 
Recruitment of the Shp2 Phosphatase. Blood. 118: 1077-1086. 
67. Gilfillan AM, Rivera J. 2009. The Tyrosine Kinase Network Regulating Mast Cell 
Activation. Immunological Reviews. 228: 149-169. 
68. Hernandez-Hansen V, Smith AJ, Surviladze Z, Chigaev A, Mazel T, 
Kalesnikoff J, Lowell CA, Krystal G, Sklar LA, Wilson BS, Oliver JM. 2004. 
Dysergulated, FcεRI Signaling and Altered Fyn and SHIP Activities in Lyn-
Deficient Mast Cells. Journal of Immunology. 173: 100-112. 
69. Kovarova M, Wassif CA, Odom S, Liao K, Porter FD, Rivera J. 2006. 
Cholesterol Deficiency in a Mouse Model of Smith-Lemli-Opitz Syndrome Reveals 
Increased Mast Cell Responsiveness. JEM. 203 (5): 1161-1171. 
70. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybluwicz VL. 2000. 
Tyrosine Kinase SYK: Essential Functions for Immunoreceptor Signaling. 
Immunology Today. 21 (3): 148-154. 
71. Chu DH, Morita CT, Weiss A. 1998. The Syk Family of Protein Tyrosine Kinases 
In T-Cell Activation and Development. Immunological Reviews. 165: 167-180. 
72. Zoller KE, MacNeil IA, Brugge JS. 1997. Protein Tyrosine Kinase Syk and ZAP-
70 Display Distinct Requirements for Src Family Kinase in Immune Response 
Receptor Signal Transduction. J Immunol. 158(4): 1650-1659.  
73. Furlong MT, Mahrenholz AM, Kim KH, Ashendel CL, Harrison ML, Geahlen 
RL. 1997. Identification of the  Major Sites of Autophosphorylation of the Murine 
Protein-Tyrosine Kinase Syk. Biochim Biophys Acta. 1355(2): 177-190. 
74. Chan AC, Dalton M, Johnson R, Kong GH, Wang T, Thoma R, Kurosaki T. 
1995. Activation of ZAP-70 Kinase Activity by Phosphorylation of Tyrosine 493 is 
Required for Lymphocyte Antigen Receptor Function. EMBO J. 14(11): 2499-2508. 
75. Zhang J, Berenstein EH, Evans RL, Siraganian RP. 1996. Transfection of Syk 
Protein Tyrosine Kinase Reconstitutes Hight Affinity IgE Receptor-mediated 
Degranulation in a Syk-negative Variant of Rat Basophilic Leukemia RBL-2H3 
Cells. J. Exp. Med. 184: 71-79. 
76. Grodzki ACG, Moon KD, Berenstein EH, Siraganian RP. 2009. FCεRI- Induced 
Activation by Low Antigen Concentrations Results in Nuclear Signals in the 
Absence of Degranulation. Molecular Immunology. 46: 2539-2547. 
77. De Castro RO. 2011. Regulation and Function of Syk Tyrosine Kinase in Mast Cell 
Signaling and Beyond. Journal of Signal Transduction. 2011: 
doi:10.1155/2011/507291. 
67 
 
78. Zhang J, Kimura T, Siraganian RP. 1998. Mutations in the Activation Loop 
Tyrosines of Protein Tyrosine Kinase Syk Abrogate Intracellular Signaling But Not 
Kinase Activity. J. Immunol. 161: 4366-4374. 
79. Hutchinson LM, Trinh BM, Palmer RK, Preziosi CA, Pelletier JH, Nelson HM, 
Gosse JA. 2011. Inorganic Arsenite Inhibits IgE Receptor-Mediated Degranulation 
of Mast Cells. Journal of Applied Toxicology. 31: 231-241. 
80. Hutchinson LM. 2011. Inorganic Arsenite Inhibits Allergic Signal Transduction in 
Mast Cells. Graduate Thesis. The Graduate School, University of Maine.  
81. Pelletier JH. 2011. Comparative analysis of toxicant effects on several distinct 
transduction pathways that all lead to degranulation in rat-derived mast cells as a 
model system. Honors Undergraduate Thesis. The Honors College, University of 
Maine.  
82. Geahlen RL, McLaughlin JL. 1989. Piceatannol (3,4,3’, 5’- tetrahydroxy-trans-
stilbene) is a Naturally Occurring Protein-Tyrosine Kinase Inhibitor. Biochemical 
and Biophysical Research Communications. 165: 241-245. 
83. Oliver JM, Burg DL, Wilson BS, McLaughlin JL, Geahlen RL. 1994. Inhibition 
of Mast Cell FcεR1-Mediated Signaling and Effector Function by the Syk-Selective 
Inhibitor, Piceatannol. The Journal of Biological Chemistry. 269 (47): 29697-29703. 
84. Matsuda H, Tewtrakul S, Morikawa T, Yoshikawa M. 2004. Anti-Allergic 
Activity of Stilbenes From Korean Rhubarb (Rheum Undulatum L.): Structure 
Requirements for Inhibition of Antigen-Induced Degranulation and their Effects on 
the Release of TNF-Α and IL-4 in RBL-2H3 Cells. Bioorganic & Medicinal 
Chemistry. 12: 4871-4876. 
85. Suzuki Y, Yoshimaru T, Yamashita K, Matsui T, Yamaki M, Shimizu K. 2001. 
Exposure of RBL-2H3 Mast Cells to Ag
+
 Induces Cell Degranulation and Mediator 
Release. Biochemical and Biophysical Research Communications. 283: 707-714. 
86. Pfeiffer JR, Oliver JM. 1994. Tyrosine Kinase-Dependent Assembly of Actin 
Plaques Linking FcεR1 Cross-Linking to Increased Cell Substrate Adhesion in RBL-
2H3 Tumor Mast Cells. J Immunol. 152:270-279. 
87. Li Z, Yang X, Dong S, Li X. 2012. DNA Breakage Induced by Piceatannol and 
Copper(II): Mechanism and Anticancer Properties. Oncology Letters. 3: 1087-1094. 
88. Hardy RR. 1986. Purification and characterization of monoclonal antibodies. 
Handbook of Experimental Immunology. D. M. Weir. Oxford, Blackwell Scientific 
Publications: 13.1-13.13. 
89. Nelson DL, Cox MM. 2008. Lehninger Principles of Biochemistry 5th Edition. W. 
H. Freeman and Company: New York. 
68 
 
90. Hornbeck P, Winston SE, Fuller SA. 2001. Enzyme-Linked Immunosorbent 
Assays UNIT 11.2 (ELISA). Curr Protoc Mol Biol. Chapter 11:Unit11.2. doi: 
10.1002/0471142727.mb1102s15. 
91. Egdal RK, Raber G, Bond AD, Hussain M, Espino MPB, Francesconi KA, 
McKenzie CJ. 2009. Selective Recognition and Binding of Arsenate over 
Phosphate. Dalton Trans. 44: 9718–9721. 
92. Hutchcroft JE, Geahlen RL, Deanin GG, Oliver JM. 1992. FcεR1-Mediated 
Tyrosine Phosphorylation and Activation of the 72-kDa Protein-Tyrosine, PTK72, in 
RBL-2H3 Rat Tumor Mast Cells. Proc Natl Acad Sci USA. 89 (19): 9107-9111. 
93. Finnegan PM, Chen W. 2012. Arsenic Toxicity: the Effects on Plant Metabolism. 
Front Physiol. 3 (182) doi: 10.3389/fphys.2012.00182. Epub 2012 Jun 6. 
94. Wang YC, Chaung RH, Tung LC. 2004. Comparison of the Cytoxicity Induced by 
Different Exposure to Sodium Arsenite in Two Fish Cell Lines. Aquat Toxicol. 
63(1): 67-79. 
95. Akter KF, Owens G, Davey DE, Naidu R. 2005. Arsenic Speciation and Toxicity 
in Biological Systems. Rev Environ Contam Toxicol. 184: 97-149.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
Author’s Biography 
Alejandro Velez Lopez Naranjo Ospina, was born in Pereira, Colombia on May 7
th
, 
1990. He was raised in several cities in Colombia and move to Johnstown, New York at 
the age of twelve. He graduated high school from New Berlin West high school in 2008 
and decided to follow his family to Hampden, Maine for college. While at the University 
of Maine, he founded Iota Nu Kappa Multicultural Fraternity and worked closely with 
the Office of Multicultural Programs to serve the campus and the surrounding 
community. As a biochemistry major, he has received the INBRE Functional Genomics 
Fellowship and the Professor Frederick H. Radke Award and was invited to participate 
in the Summer Training in Academic Research and Scholarship program through a 
partnership between Brigham and Women’s Hospital and Harvard Medical School.  
Upon graduation, Alejandro will be attending graduate school to acquire a master in 
public health with hopes of attending medical school thereafter. 
 
